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INTRODUCTION: Smoking is endemic among people with HIV and associated with 
morbidity and mortality. Little research has been conducted among smokers with HIV.  
Research has focused on examining individual-level characteristics associated with 
smoking behaviors, with little examination of social-level factors.  Aim 1 included a 
literature review concerning the intersection of HIV and smoking. Aims 2-4 explored 
individual- and social-level characteristics associated with current smoking (Aim 2), 
interest in quitting or cutting down (Aim 3), and lifetime quit attempts (Aim 4).   
 
METHODS: Data for Aims 2-4 came from a study designed to examine social 
environmental influences on HIV-positive current/former drug users’ health outcomes in 
Baltimore, Maryland.  Logistic regression (Aims 2 and 4) and multinomial logistic 




Aim 1: Literature concerning smoking among HIV-positive populations was reviewed.  
Topics included: morbidity, mortality, treatment and medication adherence outcomes; 
characteristics associated with smoking behaviors; evidence-based cessation 
interventions; findings from cessation interventions among smokers with HIV.  Gaps in 
the literature and directions for future research were identified.  
 
 ii 
Aim 2: Most participants (75%) were smokers.  Drug use (aOR=2.82, 95% CI=1.55-
5.13), 12-step program participation (aOR=1.74, 95% CI=1.02-2.96), and having a main 
Supporter who smokes (aOR=2.01, 95% CI=1.14-3.54) were associated with current 
smoking. 
 
Aim 3: Individuals who made lifetime quit attempts were more likely than those who had 
not to be interested in quitting (aRRR=3.50, 95% CI=1.39-8.30).  Family encouragement 
to smoke was negatively associated with interest in cutting down (aRRR=0.09, 95% 
CI=0.01-0.86) and interest in quitting (aRRR=0.27, 95% CI=0.08-0.90).   
 
Aim 4: Older age (45-49: aOR=3.44, 95% CI=1.60-7.39; 54-65: aOR=2.74, 95% 
CI=1.22-6.17), non-Black race (aOR=3.61, 95% CI=1.23-10.62), and having a main 
Supporter who had used NRT or medications for cessation (aOR=2.40, 95% CI=1.24-
4.63) were positively associated with an increased likelihood of lifetime use of NRT or 
medications for smoking cessation. 
 
CONCLUSIONS: Results corroborate research indicating that smoking is a significant 
public health problem among people with HIV.  Results extend knowledge by suggesting 
that social- and individual-level characteristics are associated with smoking behaviors 
among people with HIV.  Results have implications for cessation interventions among 
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1. CHAPTER 1 - INTRODUCTION 
1.1 Background 
Cigarette smoking represents an enormous public health problem, and continues 
to be the leading preventable cause of death in the United States: approximately 443,000 
persons die each year due to smoking-related causes (CDC, 2011a).  Over the past several 
decades, public health interventions have been successful in reducing the overall 
prevalence of smoking; since the mid-1960s, the prevalence of cigarette smoking has 
fallen from 42.4% to 19.0% in 2011 (CDC, 2011b; CDC, 2013).  Despite this success 
among the general population, smoking remains highly prevalent among certain 
vulnerable populations.  For instance, the prevalence of smoking among people living 
with human immunodeficiency virus (HIV) is estimated to be 40-70% (Collins et al., 
2001; Gritz et al., 2004; Mamary et al., 2002; Burkhalter et al., 2005; Crothers et al., 
2005; Lifson et al., 2010). 
This elevated prevalence is associated with a variety of negative health- and 
treatment-related outcomes.  To be more specific, elevated risks of chronic obstructive 
pulmonary disease (Lewden et al., 2005; Diaz et al., 2002; Crothers et al., 2006), 
bacterial pneumonia (Crothers et al., 2005; Lifson et al., 2010; Miguez-Burbano et al., 
2005), lung cancer (Lifson et al., 2010; Kirk et al., 2007; Chaturvedi et al., 2007; Engels 
et al., 2006), and cardiovascular disease (Lifson et al., 2010; Lewden et al., 2005; 
Petoumenos et al., 2011; Barbaro et al., 2003; Friis-Møller et al., 2003; Savès et al., 
2003), among other conditions, have been observed among HIV-positive smokers.  
Moreover, authors of a population-based Danish cohort study concluded that smokers 
with HIV lose more life-years to smoking than to HIV, and that the excess mortality of 
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smokers is tripled and the population-attributable risk of death associated with smoking is 
doubled among patients with HIV as compared to population controls (Helleberg et al., 
2013).  Additionally, in a study among females on highly active antiretroviral therapy 
(HAART), evidence has suggested that cigarette smokers are more likely than non-
smokers to have poorer treatment outcomes, including poorer viral and immunologic 
responses, greater risks of virologic rebound, more frequent immunologic failure, and a 
higher risk of developing AIDS (Furber et al., 2007; Feldman et al., 2006).  In some 
research, cigarette smoking has also been associated with poor adherence to or 
noncompliance with their HAART regimens (Feldman et al., 2006; Yuan et al., 2006; 
Shuter & Bernstein; Webb et al., 2009).  
 
1.2 Gaps in Literature and Innovation of Present Research 
 The research contained within this dissertation has the potential to contribute to 
the extant literature and scientific knowledge concerning the epidemiology of cigarette 
smoking and cigarette smoking behaviors among people living with HIV, an area of 
research that has received increasing attention, and has begun to grow over the past 
decade.  Additionally, research on cigarette smoking and HIV to date has focused 
primarily on the examination of characteristics associated with current smoking status.  
Though this research has undoubtedly yielded important findings, other smoking 
behaviors merit discussion and examination.  This dissertation aims to explore 
characteristics associated with two additional, largely as of yet unexamined smoking 
behaviors: interest in cutting down on or quitting smoking and prior use of 
pharmacologic therapies for smoking cessation.  In addition to exploring additional 
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smoking behaviors, this work makes the distinction between having an interest in simply 
cutting down on smoking versus having an interest in quitting smoking, a distinction 
often not made in previous research. 
 Furthermore, the present research extends previous work by considering social 
environmental characteristics in the analyses, in addition to individual-level 
characteristics.  Though individual-level characteristics (i.e., demographic characteristics, 
substance use, etc.) are undoubtedly important, social environmental characteristics (i.e., 
the presence of smoking in one’s environment, significant others’ smoking, family 
opinions regarding smoking, etc.) may play an important role in influencing smoking 
behaviors.  Given that smoking behavior in the general population has been consistently 
found to be associated with social network characteristics, it is very plausible that social 
environmental characteristics are associated with cigarette smoking behaviors among 
HIV-positive persons as well (Christakis & Fowler, 2008; Alexander et al., 2001; Unger 
& Chen, 1999; Mermelstein et al., 1986).  
 
1.3 Theoretical Foundation 
A visual depiction of the theoretical framework for this dissertation can be found 
in Figure 1.  The theoretical foundation for the present proposal is based on the 
combination of two different conceptual frameworks: the Ecological Model for Health 
Promotion and Social Cognitive Theory.  The Ecological model for Health Promotion 
was proposed by McLeroy and colleagues (1988), and was derived from 
Bronfenbrenner's Ecological Systems Theory (1979).  According to this model, behavior 
is viewed as being determined by a variety of different levels of influence: Intrapersonal; 
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Interpersonal; Institutional; Community; and Public policy factors.  Not all levels of the 
ecological model are represented within the present work, but two are: Interpersonal 
factors and Intrapersonal factors. Intrapersonal factors are defined as individual 
characteristics that influence behavior (McLeroy et al., 1988).  Thus, in relation to the 
present work, intrapersonal factors include individual-level characteristics like socio-
demographic characteristics, drug use, psychiatric comorbidity, and so on.  Interpersonal 
factors, on the other hand, consist of interpersonal processes and characteristics of 
primary groups including family, friends, and peers that provide social identity, support, 
and role definition (McLeroy et al., 1988).  Within the present work, interpersonal factors 
include smoking behaviors of an individual’s significant others, smoking within an 
individual’s family, and so on.  Though Institutional, Community, and Public Policy 
factors are not represented in the model concerning the current work, definitions and 
examples of each level of influence are as follows: Institutional factors are those that 
relate to the rules and regulations for operations within institutions and organizations 
(e.g., smoking bans within the workplace); Community factors are characteristics of the 
community as a geographic space (e.g., the presence of tobacco outlets in a defined 
neighborhood or community); Public policy factors include local, state, and national laws 
and policies (e.g., laws regarding determining the price of or taxation of cigarettes). 
 In addition to the Ecological Model for Health Promotion, this work draws on 
elements of Social Cognitive Theory (SCT), which posits that behavior is influenced by 
(and can reciprocally influence) personal characteristics as well as the environment 
(Bandura, 1986).  Moreover, portions of an individual’s knowledge acquisition can be 
directly related to observing others within the context of social interactions, experiences, 
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and outside media influences.  In other words, individuals do not necessarily have to 
acquire knowledge or initiate behaviors based solely on personal trial and error.  
Depending upon behaviors witnessed in the social environment, and subsequent 
consequences of the witnessed behaviors, individuals may model others’ behaviors.  This 
type of knowledge acquisition is known as vicarious learning (Bandura, 1986).  In terms 
of fitting into the overall conceptual framework, aspects of SCT are nested within the 
Intrapersonal and Interpersonal spheres of influence of the Ecological Model for Health 
Promotion.  As can be seen in Figure 1, personal characteristics (i.e., Intrapersonal factors 
in the Ecological Model for Health Promotion) and behavior share reciprocal influences, 
as do behavior and environmental characteristics (i.e., Interpersonal factors in the 
Ecological Model for Health Promotion).  Within the context of this dissertation, 
particular emphasis was placed on the vicarious learning aspect of SCT (i.e., the 
influences that environmental/Interpersonal factors have on behavior).  Correspondingly, 
one hypothesis was that observing the smoking behavior of significant others could 
influence an individual’s behavior.  For instance, individuals with significant others who 
smoke will be more likely to be smokers themselves, possibly at least in part due to 
vicarious learning. 
 
1.4 Overview of the Dissertation 
This thesis is an attempt to address the current gaps in the literature by utilizing 
data from a community-based study sample of people living with HIV and presenting 
findings concerning various smoking behaviors among this sample.  It provides the 
opportunity to examine and distinguish between the individual-level and social 
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environmental-level characteristics associated with the various smoking behaviors.  
Because it is known that cigarette smoking is highly prevalent among HIV-positive 
populations and is associated with significant morbidity and mortality, yet relatively little 
research exists to examine the intersection of HIV and smoking, this represents a 
meaningful area of investigation.  Chapter 2 contains a comprehensive critical review of 
the literature concerning cigarette smoking among people living with HIV.  In Chapter 
3, we examine the association between individual- and social-environmental 
characteristics and current smoking status.  In Chapter 4, we examine the association 
between individual- and social-environmental characteristics and two outcomes: 1) 
current interest in cutting down on smoking; and 2) current interest in quitting smoking.  
In Chapter 5, we examine the association between individual- and social-environmental 
characteristics and prior use of nicotine replacement therapy or medications for smoking 
cessation. Finally, in Chapter 6, we summarize the main conclusions from our 
investigations. 
Findings from this thesis have the potential to inform the development and 
implementation of smoking cessation interventions among a special, at-risk population, 
and subsequently to inform policies regarding best practices for smoking cessation.  
Recommendations are also provided for future research. 
 
1.5 Specific Aims and Hypotheses 
Aim 1:  Provide a comprehensive critical review of the literature concerning cigarette 
smoking among people living with HIV. 
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Aim 2: Explore the individual-level and social environmental-level characteristics 
associated with current smoking status among a sample of people living with HIV. 
Aim 2 Hypothesis: In addition to previously identified individual-level characteristics, a 
variety of social environmental-level characteristics will be associated with current 
smoking status.  In particular, the presence of cigarette smoking in an individual’s social 
network (i.e., partner, Supporter, or family smoking), as well as family members’ more 
favorable views regarding smoking will be positively associated with Index participants’ 
smoking status. 
 
Aim 3: Explore the individual-level and social environmental-level characteristics 
associated with current interest in cutting down on or quitting smoking among a sample 
of smokers living with HIV. 
Aim 3 Hypothesis: Both individual-level and social environmental-level characteristics 
will be associated with an interest in cutting down on or an interest in quitting smoking.  
In particular, having a significant other (i.e., a main Supporter) who is interested in 
quitting or cutting down or who have made prior quit attempts will be associated with an 
interest in quitting or cutting down, as will receiving encouragement from family 
members to quit smoking.  Furthermore, the associated individual-level and social 
environmental-level characteristics will differ between those with an interest in cutting 
down versus an interest in quitting smoking. 
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Aim 4: Explore the individual-level and social environmental-level characteristics 
associated with prior use of nicotine replacement therapy or medications for smoking 
cessation among a sample of smokers living with HIV. 
Aim 4 Hypothesis: Both individual-level and social-environmental level characteristics 
will be associated with prior use of nicotine replacement therapy or medications for 
smoking cessation.  In particular, having a main Supporter who has made prior quit 
attempts using pharmacologic therapies will be associated with prior use of such 
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2. CHAPTER 2 – A REVIEW OF THE LITERATURE CONCERNING HIV 
AND CIGARETTE SMOKING: MORBIDITY AND MORTALITY, 
ASSOCIATIONS WITH INDIVIDUAL- AND SOCIAL-LEVEL 
CHARACTERISTICS, AND SMOKING CESSATION EFFORTS (Aim 1) 
 
 The prevalence of cigarette smoking has been on the decline in the United States 
general population since the 1960’s, and is currently approximately 20% (CDC, 2011a).  
Despite the public health intervention successes in reducing smoking overall, certain 
subgroups of the population still exhibit an unduly high prevalence of cigarette smoking.  
For instance, among persons living with human immunodeficiency virus (HIV), the 
prevalence of cigarette smoking has been estimated to be 40-70% (Pines et al., 2011; 
Collins et al., 2001; Gritz et al., 2004; Mamary et al., 2002; Burkhalter et al., 2005; 
Crothers et al., 2005; Lifson et al., 2010).  In the past, little research attention was paid to 
the intersection of HIV and smoking.  However, the widespread availability and use of 
highly active antiretroviral therapy (HAART) has resulted in increased life expectancies 
for persons living with HIV (Palella et al., 1998).  In fact, recent estimates indicate that 
the life expectancy for an individual diagnosed with autoimmune deficiency syndrome 
(AIDS) is approximately 15 years (Walensky et al., 2006), while the life expectancy for 
individuals newly diagnosed with HIV can exceed 35 years (Lohse et al., 2007).  Along 
with increased life expectancies, the causes of death have changed significantly in the 
HAART era: mortality due to AIDS-related conditions has decreased and deaths due to 
non-AIDS-defining illnesses have increased (Palella et al., 2006).  Many of these 
conditions—such as cardiovascular disease, pulmonary conditions, and lung cancer—are 
associated with cigarette smoking.  These aforementioned statistics suggest that targeting 
cigarette smoking, a modifiable risk factor for these non-AIDS-related conditions, could 
potentially improve the quality of life and further increase the life expectancies of 
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individuals with HIV/AIDS.  In this review, we summarize the effects of cigarette 
smoking on a number of health outcomes that are relevant to people living with HIV and 
discuss issues related to smoking behavior and smoking cessation. 
 
2.1 SMOKING AND ASSOCIATED MORBIDITY, MORTALITY, AND 
MEDICAL ADHERENCE AND TREATMENT OUTCOMES 
 
2.1.1 Cardiovascular disease 
 Cardiovascular conditions have become a source of morbidity for HIV-positive 
patients.  Compared to individuals without HIV, individuals living with HIV have an 
increased risk of developing cardiovascular disease (CVD) (Lifson et al., 2010; Lewden 
et al., 2005; Petoumenos et al., 2011; Barbaro et al., 2003; Friis-Møller et al., 2003; Savès 
et al., 2003).  The high prevalence of cigarette smoking in this population may further 
contribute to the development of CVD.  In an attempt to explain the disproportionately 
high risk for CVD among people living with HIV, research has indicated that the use of 
protease inhibitors as a part of combination antiretroviral therapy may increase the risk of 
cardiovascular-related events.  Barbaro and colleagues (2003) conducted a study in which 
patients were given a HAART regimen either with or without a protease inhibitor and 
then monitored for the incidence of cardiovascular events.  Findings indicated that the 
cumulative annual incidence of CVD was higher in the group receiving protease 
inhibitors (Barbaro et al., 2003).  Additionally, although different classes of HAART 
medications and cigarette smoking both contribute to the increased risk of CVD among 
people living with HIV, findings from one study indicate that current cigarette smoking is 
associated with greater risk for myocardial infarction than protease inhibitor therapy 
(Friis-Møller et al., 2007). 
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2.1.2 Respiratory conditions 
 Research has shown that people living with HIV have elevated risks of numerous 
respiratory-related conditions, such as chronic obstructive pulmonary disease (Lewden et 
al., 2005; Diaz et al., 2002; Crothers et al., 2006) and bacterial pneumonia (Crothers et 
al., 2005; Lifson et al., 2010; Miguez-Burbano et al., 2005).  In a multicenter prospective 
study of women living with HIV, the most prominent clinical risk factor for the 
development of bacterial pneumonia in the HAART era was current cigarette smoking 
status (Kohli et al., 2006).  Miguez-Burbano and colleagues (2003) found that, after 
controlling for confounders, cigarette smoking doubled the risk for developing 




 The incidence of several types of non-AIDS-defining cancers has been found to 
be significantly higher among people living with HIV than among the general population, 
including: anal cancer, vaginal cancer, Hodgkin lymphoma, liver cancer, melanoma, 
oropharyngeal cancer, leukemia, colorectal cancer, renal cancer, and lung cancer (Patel et 
al., 2008).  Additionally, anal and cervical cancers have a higher prevalence among 
people living with HIV who are smokers than among those living with HIV who do not 
smoke (Palefsky et al., 1994; Palefsky et al., 1999).  Lung cancer is of particular interest 
given the clear association between this type of malignancy and cigarette smoking, as 
well as the fact that lung cancer is now the third most commonly diagnosed cancer 
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among people living with HIV, behind the AIDS-defining cancers Kaposi sarcoma and 
non-Hodgkin lymphoma (Kirk et al., 2007).  Compared to the general population, people 
living with HIV exhibit an elevated risk of lung cancer (Chaturvedi et al., 2007; Lifson et 
al., 2010).  Numerous studies have explored the relationship between lung cancer and 
HIV infection.  Though a few concluded that the increased prevalence of lung cancer 
among this population was attributable to heavy smoking among people living with HIV 
(Levine et al., 2010; Clifford et al., 2012), others have identified a potentially more 
complex relationship between HIV and lung cancer.  For instance, in separate analyses, 
Engels and colleagues (2006), Kirk and colleagues (2007), and Sigel and colleagues 
(2012) found that the risk of developing lung cancer among people living with HIV was 
elevated as compared to people without HIV, even after controlling for smoking status. 
 
2.1.4 Immunosuppression 
 Studies have shown that cigarette smoking has immunosuppressive effects: 
Smoking has broad immunosuppressive effects on host cell-mediated and humoral 
immune responses (Arcavi & Benowitz, 2004; Huttunen et al., 2011).  As discussed in a 
review by Sopori (2002), some studies have shown that cigarette smoking modifies 
CD4+ lymphocyte counts, though there have been inconsistencies in establishing a 
negative relationship between smoking and the course of HIV/AIDS (Furber et al., 2007).  
These findings regarding smoking and negative effects on the immune system are 
troubling, regardless of the population under investigation.  However, they are of 
particular concern among a group of people who are facing a condition that suppresses 
the immune system, such as HIV. 
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2.1.5 Medication adherence and treatment outcomes 
 Though only a few studies have included cigarette smoking in analyses as a 
potential correlate of medication adherence, among the few studies that have, findings 
indicate that cigarette smoking is associated with decreased adherence to highly active 
antiretroviral therapy (HAART).  For instance, Feldman and colleagues (2006) found that 
smokers were significantly more likely to report noncompliance with their HAART 
regimens within the past 6 months as compared to non-smokers (32.3% vs. 23%).  
Additionally, Yuan and colleagues (2006) showed that discontinuation of an initial 
HAART regimen was significantly positively associated with current cigarette smoking.  
Furthermore, among females receiving HAART in the Women's Interagency HIV Study 
(WIHS), cigarette smoking was shown to be significantly associated with decreased 
HAART adherence (Lazo et al., 2007).  Similarly, Shuter and Bernstein (2008) found 
current cigarette smoking to be an important and significant marker of inferior HIV 
medication adherence.  An additional cross-sectional study (Webb et al., 2009) found 
smoking to be negatively associated with decreased HAART adherence, and proposed 
that the relationship may be mediated by depression. 
 In terms of adverse treatment outcomes some reports suggest that cigarette 
smoking can decrease the response to highly active antiretroviral therapy (HAART) by 
40% (Miguez-Burbano et al., 2003).  In the Women’s Interagency HIV Study (WIHS), a 
cohort study of females on HAART, findings from two analyses indicate that smokers are 
more likely than non-smokers to have poorer treatment outcomes, including poorer viral 
and immunologic responses, greater risks of virologic rebound, more frequent 
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immunologic failure, and a higher risk of developing AIDS (Furber et al., 2007; Feldman 
et al., 2006).   
 
2.1.6 Quality of life 
 In addition to various morbidities, cigarette smoking is associated with decreased 
quality of life among people living with HIV.   In one analysis concerning people living 
with HIV (Turner et al., 2001), cigarette smokers were found to have lower health-related 
quality of life than non-smokers.  Specifically, cigarette smoking was associated with 
lower scores for general health perception, physical functioning, bodily pain, energy, role 
functioning, and cognitive functioning.  After adjusting for confounders, Crothers and 
colleagues (2005) found that cigarette smoking was associated with significantly lower 
quality of life as compared with never smokers.  
 
2.1.7 Death 
 Cigarette smoking remains the leading preventable cause of death among the 
general population, resulting in approximately 443,000 deaths annually (CDC, 2011b).  
Correspondingly, in addition to the aforementioned morbidity, research has shown that 
cigarette smoking is associated with death among people living with HIV.  In a United 
States-based cohort of people living with HIV receiving clinical care, current cigarette 
smoking, in addition to a low baseline CD4 cell count and older age, was an independent 
predictor of mortality (Modrich et al., 2010).  Additionally, Pines and colleagues (2011) 
showed that, compared to never smokers, current smokers were at greater risk of all-
cause mortality.  Crothers and colleagues (2005) examined more than 800 veterans in the 
United States living with HIV who were taking HAART and found that the mortality rate 
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for smokers was twice that of nonsmokers after adjusting for confounding factors like 
age, CD4 cell count, and viral load.  Additionally, authors of a large cohort study 
estimated that 24% of deaths among people living with HIV in the modern HAART era 
are attributable to tobacco use (Lifson et al., 2010).  Furthermore, results from a 
population-based Danish cohort study showed that smokers living with HIV lose more 
life-years to smoking than to HIV itself, and that the excess mortality of smokers is 
tripled and the population-attributable risk of death associated with smoking is doubled 
among patients with HIV as compared to population controls (Helleberg et al., 2013).   
 
2.2 FACTORS INFLUENCING PATTERNS OF CIGARETTE SMOKING 
Several highly interactive factors prominently associated with cigarette smoking 
patterns and behaviors can be observed among people living with HIV, including certain 
sociodemographic, drug and alcohol use, psychiatric comorbidity, and access to treatment 
characteristics.  
2.2.1 Individual-level characteristics 
2.2.1.1 Sociodemographic characteristics 
 Research among people living with HIV has fairly consistently identified several 
sociodemographic characteristics that are associated with current cigarette smoking 
status.  For instance, men are more likely than women to be current smokers among 
people living with (Mamary et al., 2002; Stewart et al., 2012).  Findings regarding age 
have been mixed, with some research indicating that younger individuals were more 
likely to be current smokers (Gritz et al., 2004), while some implicates older age 
(Tesoriero et al., 2010).  Additionally, Gritz and colleagues (2004) and Chander and 
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colleagues (2012) found that the prevalence of current cigarette smoking decreased as age 
increased.  Gritz and colleagues (2004) also found that White participants were 
significantly more likely than Hispanic participants to be current smokers.   
 
2.2.1.2 Drug and alcohol use 
 Characteristics such as heavy drinking (Gritz et al., 2004) and illegal drug use 
(Gritz et al., 2004; Burkhalter et al., 2005; Marshall et al., 2011) have been found to be 
associated with current smoking status among people living with HIV.  Additionally, in a 
study examining people with and without HIV who are injection drug users, Marshall and 
colleagues (2011) found that compared to former injectors, current injectors had a higher 
smoking prevalence, greater daily cigarette consumption, and slightly higher scores on 
the Fägerstrom Test for nicotine dependence.  In addition to associations with current 
smoking status, one study found that among HIV-positive smokers, greater current illegal 
drug use is associated with being less ready to quit smoking and being less interested in 
quitting (Burkhalter et al., 2005). 
 
2.2.1.3 Psychiatric comorbidity 
 The prevalence of depression among people living with HIV ranges from 22-32% 
(Bing et al., 2001; Ferrando & Freyberg, 2008; Rabkin et al., 1997), two to three times 
higher than what is observed in the general population.  Research has shown an 
association between depression and smoking behaviors among people living with HIV.  
Stewart and colleagues (2010) found that having depression predicted participants’ 
current smoking status.  Additionally, research has shown that higher rates of cigarette 
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smoking, greater nicotine dependence, and abuse of other substances are associated with 
a variety of mental health conditions, in addition to depression, such as schizophrenia and 
anxiety disorders (Niaura & Abrams, 2002; Ziedonis et al., 2008).  Greater levels of 
emotional stress have also been found to be associated with less readiness to quit 
smoking and less interest in quitting (Burkhalter et al., 2005). 
 
2.2.1.4 Supporting beliefs 
 In addition to the aforementioned individual-level characteristics, the beliefs held 
by people living with HIV may be important in determining or sustaining smoking 
behaviors.  For instance, self-efficacy has been found to be important in influencing 
cessation and dependence.  Vidrine and colleagues (2006) found that self-efficacy 
mediated the efficacy of cessation treatment.  Additionally, low-self efficacy to resist 
temptations and triggers to smoke has been found to be associated with nicotine 
dependence (Lloyd-Richardson et al., 2008).  Furthermore, some research has shown that 
people living with HIV believe that they will not live long enough to suffer the health 
risks of tobacco use, or they think that they are at decreased health risk for continued 
smoking (Burkhalter et al., 2005; Reynolds et al., 2004).  As a result, these individuals 
may be less concerned with smoking cessation.  
 
2.2.2 Social-level characteristics 
 To date, among people living with HIV, research examining the association 
between social environmental characteristics and cigarette smoking behaviors has been 
lacking.  Research among the general population has shown that social-level 
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characteristics influence smoking behaviors.  For instance, the presence of smoking in an 
individuals’ social network is associated with current smoking status and age of smoking 
initiation (Alexander et al., 2001; Unger & Chen, 1999).  In terms of smoking cessation, 
Christakis and Fowler (2008) found that groups of interconnected smokers tend to quit in 
concert.  Additionally, receiving high levels of support from partners, as well as 
perceived availability of support were associated with cessation and short-term 
abstinence, while the presence of smoking in one’s social network was a hindrance to 
maintaining abstinence in the long-term (Mermelstein et al., 1986). Based on this 
research conducted among the general population, it is possible that social-level 
characteristics are associated with cigarette smoking behaviors among people living with 
HIV, and have the potential to serve as important points for interventions. 
 
2.3 SMOKING CESSATION IN HIV 
2.3.1 Interest in quitting/readiness to quit 
In light of the high prevalence of smoking among people living with HIV, and the 
deleterious health concerns associated with it, it is perhaps not surprising that many 
smokers with HIV report being counseled to quit smoking.  One study reported that 81% 
of current smokers recalled receiving medical advice to quit smoking within the past year 
(Burkhalter et al., 2005).  Additionally, some studies have shown that a significant 
proportion of smokers living with HIV report being currently interested in quitting 
smoking, or are currently thinking about quitting.  For instance, Mamary and colleagues 
(2002) and Tesoriero and colleagues (2010) reported that 63% and 75% of smokers, 
respectively, were interested in quitting.  Additionally, among South African HIV clinic 
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attendees, 42% reported that they had intentions to quit smoking within the next year, and 
an additional 55% reported a desire to quit, but without having a concrete plan for 
cessation (Shapiro et al., 2011).  Though interest in quitting appears to be high among 
HIV-positive smokers, individuals may have differing perceptions of what “quitting” 
means.  For instance, in a sample of smokers living with HIV recruited from outpatient 
clinics in San Francisco, less than half (45%) of respondents chose total abstinence as a 
smoking cessation treatment goal (Humfleet et al., 2009).  Other responses included 
quitting smoking with the possibility of relapse (32.2%), abstaining for a time (5.6%), 
smoking in a controlled manner (4.4%), while the remaining respondents indicated that 
they would like to smoke occasionally (2.2%), had no clear goal (4.4%), or had some 
other goal (6.1%) (Humfleet et al., 2009).  In addition to examining interest in quitting, 
Burkhalter and colleagues (2005) and Gritz and colleagues (2004) found that 18% and 
34% of smokers living with HIV in their respective cohorts were in the preparation or 
action stages of quitting cigarette smoking.  These estimates can be contrasted with 
findings from a study conducted by Shuter and colleagues (2012a) where approximately 
two-thirds of participants with HIV surveyed at an infectious disease clinic in New York 
City indicated that they were in the preparation or action stages.  Thus, though it appears 
that interest in quitting smoking among HIV-positive smokers is high, actual readiness to 
quit tends to vary. 
In addition to exploring interest in smoking cessation, several studies have 
explored the smoking cessation modalities preferred by smokers living with HIV.  In one 
study (Shuter et al., 2012a), more than half of smokers reported interest in each of the 
following types of cessation interventions: nicotine replacement therapy (NRT) (64.4%), 
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individual counseling (64.4%), group counseling (55.9%), and using telephone quit lines 
(52.5%).  Slightly less than half of the sample reported interest in making use of a “buddy 
system”-type intervention (49.2%) or oral medications for smoking cessation (40.7%) 
(Shuter et al., 2012a).  Similar to the aforementioned findings, a study conducted by 
Shapiro and colleagues (2011) in South Africa found that the most highly endorsed 
cessation modality was free NRT (91%); much less endorsement was received for NRT 
that participants would have to pay for (28%).  Similarly, 91% of smokers reported being 
interested in utilizing free prescription medications for smoking cessation, while 26% 
would be interested in using prescription medications if they had to pay for it (Shapiro et 
al., 2011).  Additionally, many were interested in utilizing the following counseling-
based cessation methods: talking with a doctor or nurse (83%), participating in a support 
group (85%), and participating in a support group for smoking cessation that is restricted 
to persons with HIV (87%) (Shaprio et al., 2011).  Participants also reported an interest in 
using telephone quit lines (61%) and text message-based cessation support (65%) 
(Shapiro et al., 2011).  Mamary and colleagues (2002) reported that, among smokers with 
HIV currently thinking about quitting, 69% were interested in participating in a group 
smoking cessation program, 82% were interested in nicotine replacement therapy, and 
56% were interested in receiving both nicotine replacement therapy and group therapy for 
smoking cessation.  HIV-positive cigarette smokers have reported interest in a variety of 
types of smoking cessation aids and interventions, with endorsement of the same 
modalities varying between studies.  It is possible that the popularity of certain smoking 
cessation methods may vary based on the region in which the study was conducted, or 
other sample characteristics. 
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 Some research has also documented prior quit attempts made by cigarette 
smokers living with HIV.  In general, a significant proportion (33-82%) of smokers 
reported having made at least one quit attempt in the past (Benard et al., 2007; Mamary et 
al., 2002; Shapiro et al., 2011; Encrenaz et al., 2010).  Mamary and colleagues (2002) 
have found that prior quit attempts among smokers with HIV may vary based on gender: 
twice as many men reported making past quit attempts compared to women (81% versus 
40%).  Some research also indicates that many smokers (42-65%) made their quit 
attempts following receipt of their HIV diagnosis (Benard et al., 2007; Burkhalter et al., 
2005). 
2.3.2 Barriers to cessation 
2.3.2.1 Patient characteristics 
 Despite significant interest in quitting, people living with HIV, as a group, bear 
numerous characteristics that may serve as barriers to smoking cessation (Moadel et al., 
2012).  For instance, smokers living with HIV have high rates of substance use and 
comorbid psychiatric conditions (Shuter et al., 2012a).  Additionally, they are exposed to 
a variety of other stressors including poverty, racism/discrimination, stigmatization, 
loneliness, and health concerns (Encrenaz et al., 2010; Goldberg et al., 2010; Shuter et 
al., 2012a; Riley et al., 2007; Boarts et al., 2008; Bogart et al., 2008; Reynolds et al., 
2004).  As a result, these factors tend to decrease the likelihood that smoking cessation 
interventions, especially brief and “simple” interventions, will be successful among 
cigarette smokers living with HIV.   
 Beliefs held by smokers may also influence smoking cessation.  For instance, 
Shuter and colleagues (2012a) asked smokers with HIV how much they felt that cigarette 
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smoking helps them with a variety of factors.  A majority of participants felt that smoking 
helped “somewhat” or “a lot” with the following activities: controlling anxiety, 
controlling anger, controlling depression, and relaxing.  Slightly less than half of 
participants believed that smoking helped with weight control (44%), regulating bowel 
movements (39%), enhancing the high from other drugs (35.6%), increasing social 
contact (39%), and being accepted by other smokers (42.4%).  Belief that cigarette 
smoking may confer positive benefits, such as those discussed above may hamper 
smokers’ willingness to engage in smoking cessation. 
 Additionally, one study also identified several factors, related to low 
socioeconomic status, associated with difficulties in participating in a cessation program 
utilizing cellular telephones: lack of access to a working telephone, high number of 
household moves, and lack of transportation (Lazev et al., 2004).  Furthermore, the 
potential for increased toxicities, side effects and drug–drug interactions between 
antiretroviral therapies and medications for smoking cessation may complicate care. 
 
2.3.2.2 Provider characteristics 
In addition to characteristics of the smokers living with HIV themselves, 
characteristics of healthcare providers may provide barriers to cessation as well.  In 
general, smoking cessation among people with HIV has received less attention from 
practitioners.  This decreased emphasis may be due to the focus on acute treatment of 
HIV, perceived high mortality rate, lack of cessation treatment tailored to this population, 
and the perceived lack of relevance of smoking to treatment outcome and survival (Gritz 
et al., 2007).  HIV care providers may be less aware of cigarette smoking among their 
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patients than providers in the general population (Crothers et al., 2007).  This decreased 
awareness of the prevalence of smoking has the potential to impact the promotion of 
smoking cessation among people living with HIV. 
Additionally, some research shows that HIV care providers were less confident in 
their ability to achieve smoking cessation in their patients (Shuter et al., 2012b; Horvath 
et al., 2012).  For instance, in one study assessing HIV provider attitudes and practices 
regarding smoking-related services, 55% of providers surveyed reported that they were 
not confident in their ability to provide resources and advice regarding cessation to their 
patients (Horvath et al., 2012).  In another study of HIV care providers, 24.9% of 
practitioners reported that they either agreed or strongly agreed that their efforts to get 
HIV-positive smokers to quit are unlikely to succeed (Shuter et al., 2012b).   
This lack of confidence may stem from a variety of sources.  For instance, a 
majority of providers (60%) believe that their patients know that smoking is a problem, 
but do not want to quit (Horvath et al., 2012).  Additionally, approximately one-third 
(35.9%-38%) of practitioners report feeling as though they do not have adequate time to 
address smoking cessation among people living with HIV during clinic visits (Horvath et 
al., 2012; Shuter et al., 2012b).  Conversely, this diminished confidence could be due to a 
lack of training in tobacco treatment and counseling methods (Shuter et al., 2012b).  In a 
survey of providers listed in the HIV medicine Association, only 22.9% reported that 
they had ever received formal training or clinical education on this topic (Shuter et al., 
2012b).  Furthermore, a potentially troubling statistic indicates that only 29.2% of 
providers from this sample (Shuter et al., 2012b) and less than one-third of physician 
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providers from another sample (Horvath et al., 2012) would be interested in obtaining 
additional smoking-related training and educational opportunities. 
 
2.3.3 Cessation interventions 
2.3.3.1 Evidence-based smoking cessation interventions 
Each year, a significant proportion of smokers in the general population make quit 
attempts; more than half of adult smokers made a quit attempt in 2010 (CDC, 2011c).  
Success in these quit attempts varies, at least in part, based on whether or not an 
individual employs some method to aid cessation.  Research has shown that, on average, 
smokers seeking cessation assistance have twice the success with smoking cessation at 12 
months than do smokers who did not seek such assistance (Zhu et al., 2000).  Evidence-
based smoking cessation methods are varied, but can include counseling interventions, 
nicotine replacement therapy, and non-nicotine replacement therapy interventions, and 
are described below. 
 Counseling interventions can include, but are not necessarily limited to, 
individual, group, telephone, or online counseling.  Research has shown that the most 
successful counseling interventions tend to be those that are more intensive (i.e., longer in 
duration and occur over multiple visits) (Fiore et al., 2008).  For instance, brief 
interventions lasting 3 minutes resulted in abstinence rates of 13% compared to longer 
interventions lasting 10 minutes or more, which resulted in abstinence rates of 22% (Reus 
& Smith, 2008; Fiore et al., 2008).  One advantage of utilizing counseling interventions is 
that they can be provided by a variety of types of providers: physicians, nurses, social 
workers, health educators, and so on (Kwong & Bouchard-Miller, 2010). 
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 Nicotine replacement therapy (NRT) provides small doses of nicotine to the user, 
and is intended to replace the nicotine that one would receive from smoking cigarettes.  
NRT is available in several forms, including patch, gum, lozenges, inhaler, and nasal 
spray.  The patch, gum, and lozenges are available over-the-counter, without a 
prescription while nicotine inhalers and nasal sprays require prescriptions.  The amount 
of nicotine delivered by NRT varies based on the exact method used.  Moreover, the 
method of nicotine delivery from NRT products is different than when smoking 
cigarettes.  As a result, NRT can reduce, but not necessarily eliminate craving or 
withdrawal symptoms (Kwong & Bouchard-Miller, 2010).  Nevertheless, a Cochrane 
review reported that any form of NRT was more effective than placebo in helping 
smokers to quit (Stead et al., 2008). 
 Non-nicotine replacement therapy (NNRT) includes prescription medications that 
do not contain nicotine for the purpose of smoking cessation.  Two such NNRT 
medications that are often prescribed for smoking cessation include sustained-release 
bupropion (bupropion SR) and varenicline.  Buproption SR acts as a nicotinic 
acetylcholine receptor antagonist, is used to reduce the severity of nicotine cravings and 
withdrawal symptoms, and is recognized as a first-line pharmacotherapy for smoking 
cessation in the United States and Europe (Slemmer et al., 2000; Fiore, 2000; Tønnesen 
et al., 2007).  Varenicline on the other hand, is a nicotinic receptor partial agonist 
(Mihalak et al., 2006), and is used to reduce cigarette cravings as well as to decrease the 
pleasurable effects of cigarettes and other tobacco products.  Despite carrying a U.S. 
Food and Drug Administration mandated black box warning (Food and Drug 
Administration, 2009), both bupropion SR and varenicline have generally been shown to 
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be safe, and to be more efficacious than placebo (Oncken et al., 2006; Jorenby et al., 
2006; Gonzales et al., 2006) or nicotine patch (Aubin et al., 2008) in randomized 
controlled trials (RCT).  Existing RCTs have also shown varenicline to be more effective 
than bupropion SR for enabling both short- and long-term cessation (Jorenby et al., 2006; 
Gonzales et al., 2006).   
 
2.3.3.2 Smoking cessation interventions conducted among smokers living with HIV 
Despite the high prevalence of cigarette smoking and the significant associated 
health-related consequences, as well as evidence that 40-63% (Mamary et al., 2002; 
Burkhalter et al., 2005) of cigarette smokers living with HIV are at least contemplating 
smoking cessation, very few studies have investigated the effectiveness of smoking 
cessation interventions among people living with HIV.  This lack of emphasis on 
smoking cessation may be attributable to a variety of factors: the desire of 
practitioners/patients to focus on acute treatment of a life-threatening illness, a perceived 
lack of relevance of smoking to treatment outcome and survival, a lack of interventions 
tailored to the population, or the belief that other substance use treatment issues should be 
addressed first.  However, the somewhat limited existing research concerning smoking 
cessation shows promise for the use of smoking cessation strategies among smokers 
living with HIV.   
 See Table 2.1 for a summary of smoking cessation trials conducted among 
samples of people living with HIV.  Several trials have been conducted to examine the 
effectiveness of counseling-based approaches to smoking cessation among smokers 
living with HIV.  For instance, a feasibility study examining a cell phone-delivered 
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counseling intervention found that, at the end of a 2-week time period, 75% of smokers 
were abstinent (Lazev et a., 2004).  In two larger, more extensive trials of cell phone-
delivered smoking cessation interventions, smokers living with HIV receiving the phone-
delivered intervention were significantly more likely than individuals in the usual care 
group to quit smoking at 3 months (Vidrine et al., 2006: 36.8% vs. 10.3%; Vidrine et al., 
2011: 8.9% vs. 2.9%).  Moadel and colleagues (2012) found that HIV-positive smokers 
receiving a group-based smoking cessation intervention were more likely than smokers 
randomized to receive standard care to be abstinent from smoking at the 3-month follow-
up time period (19.2% vs. 9.7%).   
Additionally, studies have also examined the use of NRT for smoking cessation.  
Findings from a pilot study, conducted by Elzi and colleagues (2006), showed that 
smokers living wit HIV who received counseling plus NRT, as compared to the self-help 
control condition, were more likely to quit smoking (38% vs. 7%).  Similarly, another 
pilot study found that smokers with HIV receiving a nurse-delivered individual cessation 
counseling plus NRT reported greater abstinence rates at 8 weeks (62.5% vs. 0%) than a 
control group of smokers (Wewers et al., 2000).  Additionally, Ingersoll and colleagues 
(2009) randomized smokers living with HIV to receive self-guided reading plus the 
nicotine patch or motivational interviewing plus the nicotine patch.  No significant group 
differences were observed, although the percentage of smoking days were reduced by 
41% among both groups combined, and 22% of all participants were abstinent at follow-
up, indicating that the nicotine patch is potentially a viable smoking cessation aid option 
for HIV-positive smokers.  Furthermore, Lloyd-Richardson and colleagues (2009) 
randomized a group of smokers living with HIV to receive standard care plus the nicotine 
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patch or motivationally enhanced counseling along with the nicotine patch.  Again, 
although no group differences were observed, 6-month abstinence rates of 9-10% were 
observed for both groups.  
Furthermore, several non-randomized studies have examined the effectiveness of 
pharmacological therapies for smoking cessation among cigarette smokers living with 
HIV.  In one small study, in conjunction with physician advice participating smokers 
were given the choice of utilizing varenicline, bupropion, NRT, or no cessation aids.  At 
the end of 12 months, 25% of the sample was verified to be abstinent from smoking 
(Fuster et al., 2009).  In one study, among 21 smokers administered bupropion, 38% self-
reported abstinence from smoking at the 12-month follow-up visit (Pedro-Clotet et al., 
2006).  Two additional studies explored the effectiveness of varenicline among HIV-
positive smokers: Tornero and Mafé (2006) found that 24% of smokers administered 
varenicline were biochemically verified to be abstinent at 6 months, while Cui and 
colleagues (2011) found 42% of smokers given varenicline to be abstinent at 3 months.  
Thus, though non-significant differences were observed between intervention and control 
groups in some of the trials, and abstinence rates in intervention groups varied (8.9%-




 People living with HIV display a high prevalence of cigarette smoking, and are 
disproportionately affected by smoking-related conditions, such as cardiovascular and 
respiratory conditions, lung cancer, immunosuppressive effects, poor quality of life, and 
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adverse HIV treatment outcomes.  Despite the burden of cigarette smoking in this group, 
and the associated adverse health outcomes, relatively little research has been conducted 
among cigarette smokers living with HIV.  Additionally, among the existing research, 
much of the emphasis has been placed on examining individual-level characteristics (e.g., 
sociodemographics, psychiatric comorbidity) and their associations with patterns of 
cigarette smoking behaviors.  The extant literature has identified a variety of individual-
level characteristics, such as sociodemographics, substance use, psychiatric comorbidity, 
and supporting beliefs that are associated with current smoking status, interest in quitting, 
and barriers to cessation.  Though these types of characteristics are undoubtedly 
important in helping to elucidate patterns of smoking, barriers to cessation, and so on, 
additional research should be conducted to examine social-level characteristics and their 
associations with cigarette smoking among people living with HIV.  The omission of 
social-level characteristics in extant research is notable, given that prior research among 
the general population has shown such characteristics to be associated with cigarette 
smoking behaviors.  Additionally, much of the existing research has focused on 
examining characteristics associated with current cigarette smoking status among people 
living with HIV.  Again, though this is certainly a behavior of much interest, other 
cigarette smoking behaviors are worthy of investigation as well.  Future research should 
include the examination of characteristics associated with additional smoking behaviors, 
such as quit attempts and cessation success. 
 Prior research has also examined and identified numerous provider-related 
characteristics that may serve as barriers to smoking cessation among smokers with HIV.  
Some of the most notable and troubling findings concern HIV care providers’ lack of 
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training in smoking cessation and counseling methods, as well as physicians’ lack of 
interest in participating in such educational programs in an attempt to receive more 
training.  Given the nearly ubiquitous nature of cigarette smoking among HIV-positive 
persons, it would seem prudent to include some form of smoking cessation-related 
training as part of HIV care providers’ education, regardless of their level of interest in 
such education.  Having experience with this type of training may increase providers’ 
self-efficacy for successfully providing smoking cessation advice and therapy to their 
patients, and subsequently increase cessation attempts and eventual cessation among 
smokers living with HIV. 
 Furthermore, few published studies and randomized controlled trials exist 
concerning smoking cessation interventions among people living with HIV.  Additional 
research is needed in this area to determine which smoking cessation modalities are 
effective in this population, as well as to investigate the potential for adverse drug-drug 
interactions when using pharmacological therapies for smoking cessation, as few studies 
have looked into this among people living with HIV.  In addition to investigating the 
effectiveness of smoking cessation therapies, given the high prevalence of smoking and 
the deleterious associated health consequences, the feasibility and cost-effectiveness of 
integrating smoking cessation therapy within HIV care settings should be investigated.  
Furthermore, the belief that addressing cigarette smoking is not a priority is prevalent 
among people living with HIV as well as among their healthcare providers.  Such issues 
suggest the need for educational efforts to inform providers and patients about the 
healthcare, adherence, and treatment risks associated with cigarette smoking among 
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Table 2.1. Summary of studies investigating evidence-based smoking cessation modalities among samples of persons living 
with HIV 
Study R/NR Intervention(s) n Follow-up Outcome - 
abstinence 
Cui, 2011 NR Varenicline  36 3 months (BCV) 42% (15/36) 
Elzi, 2006 NR Counseling + NRT; no 
treatment control 
34; 383 12 months (SR) 38% (13/34);  
7% (27/383) 
Fuster, 2009 NR Varenicline, bupropion, 
NRT, no aids 
6; 12; 8; 3 12 months 
(BCV) 
25% (8/32) 
Ingersoll, 2009 R NRT + self help; NRT + 
motivational interviewing 
18; 22 3 months (BCV) 22% (9/40) overall; 
ns group difference 
Lazev, 2004 NR Cell phone counseling 19 2 weeks (SR) 75% (15/19) 
Lloyd-Richardson, 2009 R NRT + motivational 
interviewing; NRT + 
standard care 
232; 212 6 months (BCV) 9% (21/232);  
10% (21/212) –  
ns group difference 
Moadel, 2012 R Group treatment; standard 
care 
73; 72 3 months (BCV) 19.2% (14/73);  
9.7% (7/72) 
Pedro-Clotet, 2006 NR Bupropion 21 12 months (SR) 38% (8/21) 
Tornero, 2009 NR Varenicline 22 6 months (BCV) 24% (5/21) 
Vidrine, 2006 R Cell phone counseling; 
standard care 
48; 47 3 months (BCV) 36.8% (14/38); 
10.3% (4/39) 




3 months (BCV) 8.9% (21/236); 
2.9% (7/238) 
Wewers, 2000 R Peer-led intervention + 
NRT; no treatment control  
8; 7 8 weeks (BCV) 62.5% (5/8);  
0% (0/7) 
Definitions of abbreviations: R/NR = randomized/non-randomized; BCV = biochemically verified; SR = self-report; NRT = 
nicotine replacement therapy; ns = non significant
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3. CHAPTER 3 – THE ASSOCIATION OF INDIVIDUAL-LEVEL AND SOCIAL-
LEVEL CHARACTERISTICS WITH CURRENT CIGARETTE SMOKING 
STATUS AMONG A SAMPLE OF PEOPLE LIVING WITH HIV (Aim 2) 
 
Abstract: Cigarette smoking is endemic among people living with HIV and is related to 
substantial morbidity and mortality.  Research has largely focused on individual-level 
characteristics associated with smoking, with less attention to social factors.  We aimed 
to explore individual- and social-level characteristics associated with current cigarette 
smoking among people living with HIV.  Data came from 358 individuals on 
antiretroviral therapy interviewed in a study on informal HIV caregiving conducted in 
Baltimore, Maryland.  Most participants (75%) were current smokers and 45% reported 
current drug use. In adjusted logistic regression analyses, current drug use (adjusted odds 
ratio (aOR)=2.82, 95% confidence interval (CI)=1.55-5.13), 12-step program 
participation (aOR=1.74, 95% CI=1.02-2.96), and having a main Supporter who is a 
current smoker (aOR=2.01, 95% CI=1.14-3.54) were associated with current smoking.  
Findings reveal the importance of social-level factors in cigarette smoking among HIV-
positive drug users and have implications for developing targeted smoking cessation 










 Cigarette smoking is the leading preventable cause of death in the United States 
(US) (CDC, 2011a).  While the prevalence of smoking among the general population is 
approximately 20% (CDC, 2011b), the prevalence of smoking is estimated to be 40-70% 
among people living with HIV (Collins et al., 2001; Gritz et al., 2004; Mamary et al., 
2002; Burkhalter et al., 2005; Crothers et al., 2005; Lifson et al., 2010).  This disparity is 
potentially reflective of the higher prevalence of cigarette smoking among substance 
using populations (70-90%) in the United States (Richter et al., 2002; Clarke et al., 2001), 
a group that bears a disproportionate burden of HIV in the US (CDC 2011c; CDC, 2002).   
As life expectancies among people living with HIV continue to increase due to 
advancements in treatments for HIV, greater attention has been directed to the 
intersection of tobacco use and HIV.  Along with increased life expectancies, an 
increased incidence of non-AIDS-related conditions has been observed in this population, 
many of which are associated with cigarette smoking.  Elevated risks of chronic 
obstructive pulmonary disease (Lewden et al., 2005; Diaz et al., 2002; Crothers et al., 
2006), bacterial pneumonia (Crothers et al., 2005; Lifson et al., 2010; Miguez-Burbano et 
al., 2005), lung cancer (Lifson et al., 2010; Kirk et al., 2007; Chaturvedi et al., 2007; 
Engels et al., 2006), and cardiovascular disease (Lifson et al., 2010; Lewden et al., 2005; 
Petoumenos et al., 2011; Barbaro et al., 2003; Friis-Møller et al., 2003; Savès et al., 
2003) have been observed among populations of persons living with HIV.  Furthermore, 
cigarette smoking among people living with HIV is associated with significant mortality.  
Authors of a population-based Danish cohort study concluded that smokers with HIV 
lose more life-years to smoking than to HIV, and that the excess mortality of smokers is 
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tripled and the population-attributable risk of death associated with smoking is doubled 
among patients with HIV as compared to population controls (Helleberg et al., 2013).  
Additionally, as discussed in a review by Sopori (2002), some studies have shown that 
cigarette smoking modifies CD4+ lymphocyte counts, though there have been 
inconsistencies in establishing a negative relationship between smoking and the course of 
HIV/AIDS (Furber et al., 2007).  Nonetheless, in a study among females on highly active 
antiretroviral therapy (HAART), evidence has suggested that cigarette smokers are more 
likely than non-smokers to have poorer treatment outcomes, including poorer viral and 
immunologic responses, greater risks of virologic rebound, more frequent immunologic 
failure, and a higher risk of developing AIDS (Furber et al., 2007; Feldman et al., 2006). 
 Although prior research has explored factors associated with cigarette smoking 
among people living with HIV, the studies have largely been limited to the examination 
of individual-level characteristics.  For example, demographic characteristics such as sex 
(Stewart et al., 2012; Mamary et al., 2002), age (Gritz et al., 2004; Tesoriero et al., 2010), 
race/ethnicity (Gritz et al., 2004), education (Gritz et al., 2004; Chander et al., 2012) and 
comorbid depression (Stewart et al., 2012), as well as behavioral characteristics such as 
heavy drinking (Gritz et al., 2004) and illegal drug use (Gritz et al., 2004; Burkhalter et 
al., 2005) have been found to be associated with current cigarette smoking among people 
living with HIV.  To date, research examining the influence of social environmental 
characteristics such as dyadic-level (i.e., characteristics relating to interactions or 
relationships between two individuals, the smallest possible social group) and family-
level characteristics, and their association with current cigarette smoking among people 
with HIV has yet to be explored.  Examination of such social environmental factors has 
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the potential to ultimately yield information helpful in the development of smoking 
cessation interventions for people living with HIV. 
 In the general population, smoking behaviors are consistently associated with 
social network factors (Christakis & Fowler, 2008).  Research among adolescent smokers 
has shown that the presence of smoking in an individual’s network increases their risk of 
smoking (Alexander et al., 2001) and is associated with an earlier age of smoking 
initiation (Unger & Chen, 1999) as compared to adolescents whose network does not 
contain smokers.  Social factors also appear to play a role in smoking cessation. Social 
network analysis indicates that groups of interconnected individuals quit smoking in 
concert (Christakis & Fowler, 2008).  Additionally, specific social factors may function 
at different times within the quitting process to help or hinder cessation maintenance. For 
instance, high levels of support from partners, as well as perceived availability of support 
are associated with cessation and short-term abstinence (Mermelstein et al., 1986).  
Conversely, having social network members who were smokers was a hindrance to 
maintaining abstinence in the long-term (Mermelstein et al., 1986).  It is likely that these 
social factors are also influential of smoking among people living with HIV, given their 
previously observed association with smoking behaviors among the general population 
(Christakis & Fowler, 2008; Alexander et al., 2001; Unger & Chen, 1999; Mermelstein et 
al., 1986). 
 In light of the aforementioned gaps in the literature, the aim of the present study 
was to examine individual and social environmental characteristics and their association 
with current cigarette smoking among a sample people living with HIV.  The theoretical 
foundation for these analyses is based on a combination of the Ecological Model for 
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Health Promotion (McLeroy et al., 1988) and Social Cognitive Theory (SCT; Bandura, 
1986).  The Ecological Model for Health Promotion and SCT both posit that various 
levels of influence can impact an individual’s behavior.  For instance, within the 
Ecological Model, two levels of influence include Intrapersonal (i.e., individual-level 
characteristics) and Interpersonal characteristics (i.e., characteristics of primary groups 
such as family, friends, and peers).  Additionally, in SCT, an individual’s behavior is 
influenced by (and can reciprocally influence) personal characteristics of the individual 
as well as by the environment.   In light of these conceptual frameworks and findings 
from prior research, we hypothesized that individual-level characteristics such as current 
substance use, and social environmental factors such as the presence of smoking in 
dyadic relationships and norms regarding smoking in the network would be associated 
with current cigarette smoking.  The association of individual- and social-level factors 
with smoking may represent important targets for smoking cessation interventions.  
 
3.2 Methods 
3.2.1 Data Source 
 Data were from the 6-month follow-up assessment of the BEACON (BEing 
Active & CONnected) Study, a longitudinal study with three semi-annual visits aimed at 
examining social environmental influences on former and current drug users’ HIV 
medication adherence and health outcomes.  The study (2006-2012) was conducted in 
Baltimore, Maryland, US.  Follow-up rates were 94% and 86% at the 6- and 12-month 
follow-up visits, respectively.  The study enrolled Index participants on antiretroviral 
therapy, recruited from clinic and community venues; and up to two of Indexes' main 
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supportive ties whom the Indexes authorized our recruitment, with recruitment selection 
priority based on degree of providing the Index emotional support and instrumental 
assistance.  Index participants were considered eligible if they were HIV-positive and 
either current or former injection drug users, 18 years of age or older, and were on HIV 
treatment at the time of study enrollment.  Supporter participants were considered eligible 
if they were 18 years of age or older, and were verified to not be professionals whose 
only relationship with the Index was in the capacity of service provider.  Index 
participants were recruited from the Johns Hopkins University Moore Clinic for HIV 
Care, the largest HIV care provider in Maryland, as well as via targeted street-outreach.  
Data were collected by trained interviewers and via audio computer-assisted self-
interviewing (ACASI). Index and Supporter dyads were administered questionnaires at 
similar time points.  Information regarding the characteristics of Index and Supporter 
participants was self-reported by the Indexes and Supporters, respectively.   
The questionnaire for each of the three semi-annual visits gathered information on 
medication adherence, illegal drug use, and mental health variables.  However, the 6-
month follow-up visit contained more extensive information regarding cigarette smoking 
than either the baseline visit or 12-month follow-up visit.  As a result, the present study 
utilized data from the 6-month follow-up visit.  The sample for the present analysis 
comprised 358 Index participants (94% of the baseline sample); one Index case was 
excluded because of missing data.  The Institutional Review Board at Johns Hopkins 
University Bloomberg School of Public Health approved this study.   
3.2.2 Measures 
3.2.2.1 Individual-level variables 
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Sociodemographic variables - Sociodemographic variables selected for this 
analysis includes sex, age, race, past month income, and marital status.  Sex was 
dichotomized (male/female), and age was categorized into approximate quartiles (28-44; 
45-49; 50-53; 54-65).  Race was dichotomized as “Black” or “non-Black” due to sample 
distribution.  Past month income from all sources, including food stamps was 
dichotomized (<$500 versus >$500).  Marital status was also dichotomized as “not 
married” or “married or in a committed relationship”. 
Drug and alcohol use - Individuals were dichotomized based on self-reported use 
of alcohol within the past month.  Participants were also asked about the frequency with 
which they use other substances for extramedical purposes (i.e., stimulants, opiates, 
tranquilizers or barbiturates, marijuana, heroin, cocaine or crack, hallucinogens, 
prescription drugs, and “other drugs” within the past month).  Participants that reported 
using any of these substances at least once within the past month were categorized as 
past-month users for each substance.  A dichotomous composite variable was also created 
for “any past month drug use”, not including alcohol.  Additionally, individuals were 
dichotomized based on self-reported injection drug use in the past 6 months. 
Depressive symptoms - The Center for Epidemiologic Studies Depression Scale 
(CES-D) is a short (20 item) self-report scale designed to measure depressive 
symptomatology in the general population (Radloff, 1977).  The items of the scale 
correspond to symptoms that are associated with major depressive disorder, which have 
been used in previously validated longer scales.  Possible range of scores is 0 to 60, with 
higher scores indicating the presence of more symptomatology.  A score of 16 or higher 
has been used to identify individuals with clinically meaningful depressive symptoms 
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(Radloff, 1977).  The CES-D has been shown to be valid among a sample of low 
socioeconomic status, primarily African American individuals (Thomas et al., 2001), and 
has been used widely among samples similar to the one utilized for the present work 
(Yang et al., 2013; Latkin et al., 2012).The CES-D has been shown to have very good 
internal consistency reliability (>0.85) and acceptable test-retest reliability (Radloff, 
1977; Hann et al., 1999).  Additionally, it has been shown to have moderate-good (0.44-
0.75) concurrent validity compared with other scales measuring depressive symptoms 
(Radloff, 1977), good discriminant validity (Weissman, 1977), and sensitivity of 0.95 and 
specificity of 0.70 when compared with the Diagnostic Interview Schedule for DSM-IV 
(Thomas et al., 2001). 
HIV primary care visits & drug treatment utilization - Based on the distribution in 
exploratory analyses, the number of HIV primary care visits in the past 6 months was 
categorized as approximate tertiles (0-2; 3-4; 5+).  Utilization of 12-step programs was 
also used as a dichotomous variable (yes/no). 
Cigarette smoking - Participants were asked whether they had smoked cigarettes 
in the past 30 days.  A dichotomous variable (yes/no) was created based on the responses, 
and individuals reporting past 30 day smoking were considered to be current smokers.  
Current smokers were also questioned about the number of cigarettes that they smoke per 
day (i.e., cigarettes per day (CPD): <1, 1-10, 11-20, 21+), how soon after waking they 
smoke their first cigarette of the day (i.e., time to first cigarette (TTFC): <5 minutes, 6-30 
minutes, 31-60 minutes, and 60+ minutes), as well as prior use of nicotine replacement 
therapy (yes/no), and prior use of medications or pills for the purpose of smoking 
cessation (yes/no).   
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Additionally, the Heaviness of Smoking Index (HSI) (Heatherton et al., 1989), a 
measure of nicotine dependence was created using the CPD and TTFC measures.  Scores 
for the HSI range from a possible 0 to 6, with higher scores indicating a higher level of 
probable dependence.  As done in prior research (Chaiton et al., 2007), the HSI was 
categorized into a 3-category variable: low (0-1), medium (2-4), and high (5-6).  The HSI 
has been shown to have good test-retest reliability (0.72) over a 3-year period (Borland, 
2010), good sensitivity (0.79) and specificity (0.96), and good concordance (Cohen’s 
kappa=0.74) with the Fagerström Test for Nicotine Dependence (Heatherton et al., 1989), 
the most widely used measure of nicotine dependence (Chabrol et al., 2005). 
3.2.2.2 Dyadic-level variables 
A dichotomous variable was created based on participants’ responses to a 
question asking if their main partner currently smoked.  Another dichotomous variable 
was created based on Supporters’ responses to a question asking if they currently 
smoked.  Supporters were administered questionnaires similar to those given to Index 
participants, described previously, and contained information regarding 
sociodemographic characteristics, cigarette smoking, HIV status, and drug and alcohol 
use. 
Not all participants reported having a main partner or a main Supporter: 192 
(54%) Indexes reported having a main partner and 229 Index participants (64%) had a 
corresponding main Supporter.  In order to utilize the full sample (n=358), the two 
dyadic-level variables were coded as “0” (i.e., “no”) for individuals without partners or 
Supporters.  This was deemed reasonable, since the Index participants without main 
partners or Supporters would not have had the influence of cigarette smoking by partners 
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or Supporters at that point in their lives.  Sensitivity analyses were also performed that 
justify this decision. 
3.2.2.3 Family-level variables 
  Several dichotomous (yes/no) variables were created based on Index participants’ 
responses to questions regarding the following topics: prevalence of smoking among 
family members; encouragement to smoke by family members; family members’ belief 
that smoking causes health problems; whether family members dislike cigarette smoking; 
and whether family members have rules regarding where someone can or cannot smoke 
within their homes. 
3.2.3 Statistical Analysis 
 Chi-square (χ2) tests were used to assess the statistical significance of 
relationships between current cigarette smoking status and individual-level, dyadic-level, 
and family-level variables.  Unadjusted and adjusted logistic regression analyses were 
used to calculate odds ratios (ORs), adjusted odds ratios (aORs), and 95% confidence 
intervals (CI).  Variable selection for the adjusted model was based on evidence from 
prior literature, a priori theory, or χ2 p-values of <0.05.  Variables selected for the 
adjusted model included: sex, age, marital status, income, past 30 day alcohol use, any 
past 30 day drug use, depressive symptoms, past 6 month participation in a 12-step 
program, family smoking, main partner smoking, and main supporter smoking.    
 Of the 359 individuals followed up at the 6-month interview, 358 provided 
information on current smoking status.  These 358 individuals comprised the study 
sample for the present analysis.  Analyses were also performed among only those 
individuals who had a main Supporter in an effort to assess how the decision to code the 
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two dyadic-level variable for Supporter smoking status as “0” (i.e., “no”) for individuals 
without Supporters affected results.  All analyses were performed using STATA SE 
statistical software version 12.0 (StataCorp, 2011). 
 
3.3 Results 
3.3.1 Index participant characteristics 
Participant characteristics are shown in Table 3.1.  Three-quarters (75%) of the 
sample reported current cigarette smoking.  The majority of the sample were male 
(61.8%), Black (92.2%), reported a past month income of $500 or more (82.5%), and 
were not married (68.2%).  More than a quarter of the sample was between the ages of 
45-49 (27.3%), and the mean age was 48.9 years (SE=0.33).  Approximately 38% of the 
sample had a CESD score of 16 or greater, indicating clinically meaningful depressive 
symptoms.  In the past 6 months, 43.6% reported making 0-2 visits to their HIV primary 
care physician, 23.6% made 3-4 visits, and the remaining 32.9% reported making 5 or 
more visits.  Additionally, 52.8% of participants reported engaging in a 12-step program 
in the past 6 months.  A sizeable portion of the sample (37.9%) reported consuming 
alcohol in the past month, and the prevalence of alcohol use differed by current smoking 
status, with current smokers being more likely to report alcohol use (χ2 (1, N = 358) = 
3.87, p = 0.049).  Current smokers were also more likely than non-smokers to report any 
past month drug use (χ2 (1, N = 358) = 15.98, p < 0.001) as well as past 6-month injection 
drug use (χ2 (1, N = 358) = 5.16, p = 0.023).   
Of the full sample, forty-one percent of the sample reported having a main partner 
who smoked, though this did not differ by Index smoking status.  Conversely, current 
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cigarette smokers were more likely to have a main Supporter who was also a smoker than 
were non-smokers (χ2 (1, N = 358) = 6.67, p = 0.010). 
A majority of the sample reported that their family contains current smokers 
(83.2%), and current smokers were more likely than non-smokers to have smokers in 
their family (85.5% vs. 76.4%, respectively) (χ2 (1, N = 358) = 3.97, p = 0.046).  Despite 
this, the majority of the sample reported that their family believed that smoking causes 
health problems (96.9%), dislikes cigarette smoke (89.4%), and has rules about where 
people can and cannot smoke in their houses (87.4%).  Few participants reported 
receiving encouragement from their family members to smoke (8.4%). 
3.3.2 Smoking characteristics 
 Cigarette smoking characteristics are shown in Table 3.2.  The majority of the 
current sample (74%) reported current cigarette smoking.  Of the 267 current smokers, 
most (76%) reported smoking 1-10 cigarettes per day (CPD), and smoking their first 
cigarette of the day within 5 minutes of waking (34%).  More than half (64%) of the 
current smokers exhibited a medium-level of nicotine dependence, as assessed by the 
HSI.  Fifty-seven percent of smokers reported previous experience with nicotine 
replacement therapy, and 9% reported previously using pills or medication for smoking 
cessation. 
3.3.3 Drug use 
 Detailed information on drug use is shown in Table 3.3.  Approximately 28% and 
21% of the sample reported using cocaine/crack cocaine and heroin, respectively, in the 
past 30 days; current smokers were significantly more likely to report both cocaine/crack 
cocaine use (χ2 (1, N = 358) = 11.21, p = 0.001) and heroin use (χ2 (1, N = 358) = 4.99, p 
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= 0.026) than were non-smokers.  Smaller proportions of the sample reported using 
stimulants other than cocaine/crack cocaine (0.8%) and opiates other than heroin 
(13.1%).  Tranquilizers and/or barbiturates were used in the past 30 days by 4.5% of the 
sample, with smokers being more likely to report use (χ2 (1, N = 358) = 5.54, p = 0.019).  
One-fifth (20.1%) of the sample reported past month use of marijuana, and once again, 
current smokers were significantly more likely to report marijuana use than were non-
smokers (χ2 (1, N = 358) = 7.37, p = 0.007).  Few participants reported past month use of 
hallucinogens (0.1%), prescription drugs (3.3%), or other drugs (0.8%).   
3.3.4 Logistic regression analyses 
 See Table 3.4 for information regarding unadjusted and adjusted logistic 
regression models.  Logistic regression analyses were all completed with current smoking 
status as the outcome.  After including all covariates in the adjusted logistic regression 
model, several individual-level factors were found to be statistically significant.  
Participation in a 12-step program was found to be significantly associated with current 
cigarette smoking (aOR=1.74, 95% CI=1.02-2.96).  Additionally, any drug use in the past 
30 days continued to be significantly associated with current smoking (aOR=2.90, 95% 
CI=1.59-5.31) in the adjusted model.  Among dyadic-level characteristics assessed, 
having a main supporter who smokes also continued to be associated with current 
cigarette smoking (aOR=1.91, 95% CI=1.08-3.82) in the final adjusted logistic regression 
model.  Other dyadic-level characteristics, specifically smoking status of a main partner, 
were not associated with the smoking status of the Index participant (aOR=1.04, 95% 
CI=0.56-1.93). 
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3.3.5 Supporter characteristics 
 In light of findings from the adjusted logistic regression analyses, we explored 
characteristics of Supporter individuals.  See Table 3.5 for information regarding 
Supporter characteristics.  The majority of Supporters were female (58.1%), with a mean 
age of 47.8 years (SE=0.73).  The majority of Supporters were Black (92.6%), had a past 
month income of $500 or greater (74.1%), and approximately half were married (47.2%) 
and had HIV (46.6%).  Approximately 41% of Supporters live with their Index.  In terms 
of type of relationship to their Index participant, 43.2% of Supporters were their Index’s 
partner, 27.1% were kin, and 29.3% were of some “other” relationship (i.e., friend, 
neighbor, etc.) to their Index.  Furthermore, 35.8% of Supporter-Index relationships were 
same sex dyads (i.e., male Supporter, male Index), and the remaining 64.2% were 
opposite sex dyads (i.e., male Supporter, female Index).  Approximately half (48.5%) of 
Supporters reported using alcohol in the past month, and 40.8% reported past month drug 
use. 
3.3.6 Sensitivity analyses 
 In adjusted analyses, when restricting the sample to the 229 individuals who had a 
main Supporter, the finding pertaining to 12-step program utilization was no longer 
statistically significant, though the association remained positive (aOR=1.45, 95% 
CI=0.72-2.92).  Drug use within the past 30 days (aOR=2.65, 95% CI=1.18-5.94) and 
Supporter smoking status (aOR=4.12, 95% CI=1.96-8.67) continued to be positively and 
statistically significantly associated with Index current cigarette smoking status.  No other 
differences were observed between findings from the full sample (n=358) and the 




 Findings from the present study identified several characteristics, both individual 
and social environmental, that are associated with current cigarette smoking in adjusted 
models among a sample of people living with HIV.  In terms of individual-level 
characteristics, past month use of illicit drug use was strongly associated with current 
cigarette smoking among this sample of people with HIV.  This finding is consistent with 
prior research conducted in both HIV-positive (Gritz et al., 2004; Burkhalter et al., 2005) 
and general populations (Richter et al., 2002).  Additionally, individuals reporting 
utilization of a 12-step program in the past 6 month were significantly more likely to be 
current smokers than were those not engaging in such programs.  One potential 
explanation for this finding is that within some treatment communities, major life 
changes during the early portions of the recovery process are discouraged for fear of 
triggering relapse, and the treatment culture has accepted that quitting tobacco use would 
constitute a major life change (Sussman, 2002; Joseph et al., 2002).  Additionally, in 
some treatment organizations, smoking is a part of the staff culture, where staff members 
take smoking breaks with one another, and sometimes even with their clients (Ziedonis et 
al., 2006).  Interestingly, a sizeable proportion of the sample reported engaging in recent 
contact with an HIV care provider or a 12-step program.  Each of these interactions with 
healthcare professionals represents a unique opportunity to address smoking cessation. 
 A novel finding in the present analyses included the observed association between 
cigarette smoking between a main Supporter and current smoking of Index participants.  
Smoking by a main Supporter was associated with a nearly two-fold increased odds of 
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current smoking relative to Index participants whose Supporter was a non-smoker.  
Interestingly, the same findings did not hold when examining the association between 
main partner smoking and current smoking by Index participants.  This disparity may 
arise due to the differing social roles filled by main partners and main Supporters.  Main 
Supporters, as defined in this study, are those individuals who are most supportive of the 
Index in their living with HIV; while main partners tend to be individuals with whom 
Index participants are engaged in a sexual relationship (i.e., boyfriend/girlfriend, 
husband/wife).  It should also be noted that some main partners and main Supporters are 
the same individual for a specific Index participant: 43% of main Supporters are also 
their respective Index participant’s main partner.  Given that Supporters’ smoking status 
is associated with Indexes’ smoking status, this relationship may present an important 
potential point for implementing smoking cessation interventions. 
 Findings from sensitivity analyses, whereby the sample was restricted to only 
those individuals who had a Supporter, yielded minimal differences from analyses 
utilizing the full sample.  One exception is that in analyses from the full sample, 12-step 
program participation was positively associated with current smoking, while in the 
restricted sample, this association was not statistically significant.  This discrepancy may 
be due to loss of statistical power when reducing the sample size.  This lack of observed 
differences in findings between the full and restricted samples potentially indicates that 
the decision to use the full sample in order to increase statistical power was justified.  
The present study has several limitations that should be acknowledged.  For 
instance, this research utilizes cross-sectional data; therefore temporal relationships 
between variables cannot be clearly determined.  Also, generalizability of the findings 
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may be limited due to the unique nature of the population. Additionally, all data were 
collected via self-report, which carries the inherent possibility for social desirability bias.  
In attempt to mitigate this possibility, data were collected using audio computer-assisted 
self-interviewing (ACASI), which has been shown to improve the likelihood of valid 
reporting of sensitive information (Macalino et al., 2002).  Furthermore, the survey does 
not contain sociometric social network data (i.e., data in which the entire community, or 
as many as possible, are interviewed, and all respondents are asked about their contacts 
within the community) (Wasserman & Faust, 1994).  With sociometric data, one might be 
able to obtain additional information, including the density of smoking in the network, 
the types of relationships between smokers and Index participants, and the specific 
support provided by smokers.  Finally, the survey does not include information on 
duration of smoking, or past smoking behaviors, and also did not collect information on 
the prevalence of cigarette smoking in the Index participant’s larger social network, 
outside of their family, main partner, or main supporter. 
Notwithstanding these limitations, the study possesses several strengths.  Results 
from this study contribute to the extant literature concerning factors that are associated 
with cigarette smoking among people living with HIV—a population exhibiting an high 
prevalence of cigarette smoking and, consequently, bearing a disproportionate burden of 
smoking-related morbidity—by investigating social environmental variables associated 
with smoking.  Additionally, this study focuses on and provides information on a 
prevalent and typically hard-to-reach population. 
 In summary, this study confirms prior research that indicates that cigarette 
smoking is highly prevalent among people living with HIV, and corroborates previous 
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research findings showing that individual-level factors, such as recent illicit drug use, are 
associated with cigarette smoking among people with HIV.  Findings from this study also 
extend existing research by demonstrating that social factors, specifically that a main 
Supporting individual’s smoking behavior is associated with Index participants’ current 
smoking status.  These findings are significant in that they contribute to an increased 
understanding of the factors that are related to smoking among a high-risk population.  
Furthermore, they have potential implications for the development of smoking cessation 
treatment interventions.  Given the high prevalence of smoking among people living with 
HIV, it may be prudent to integrate smoking cessation efforts with HIV primary care 
settings.  Findings from this study also emphasize that members of an individual’s social 
network may strongly influence their smoking behaviors.  Smoking cessation 
interventions with a social component, namely ones that involve main Supporter 
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Table 3.1. Characteristics of people living with HIV, stratified by smoking status, 
BEACON, 2006-2012 (n=358) 
 Total Sample Current smoking  





  n (%) n (%)  
Characteristic     
Individual-Level     
Sex     
Male 222 (61.8) 59 (66.3) 163 (60.6) 0.337 
Female 137 (38.2) 30 (33.7) 106 (39.4)  
Age     
28-44 87 (24.2) 20 (22.5) 66 (24.5) 0.239 
45-49 98 (27.3) 23 (25.8) 75 (27.9)  
50-53 89 (24.8) 18 (20.2) 71 (26.4)  
54+ 85 (23.7) 28 (31.5) 57 (21.2)  
Age (Mean (SE)) 48.9 (0.33) 49.5 (0.70) 48.6 (0.37) 0.240 
Race     
Black 330 (92.2) 86 (96.6) 244 (90.7) 0.071 
Non-black 28 (7.8) 3 (3.4) 25 (9.3)  
Income     
<$500 64 (17.5) 13 (14.6) 51 (19.0) 0.353 
$500+ 302 (82.5) 76 (85.4) 218 (81.0)  
Marital status     
Not married 244 (68.2) 60 (67.4) 184 (68.4)  
Married/committed 
relationship 
114 (31.8) 29 (32.6) 85 (31.6) 0.863 
CESD Score     
<16 223 (62.3) 60 (67.4) 163 (60.6) 0.250 
16+ 135 (37.7) 29 (32.6) 106 (39.4)  
HIV Primary Care Visitsa     
0-2 156 (43.6) 42 (47.2) 114 (42.4) 0.641 
3-4 84 (23.6) 18 (20.2) 66 (24.5)  
5+ 118 (32.9) 29 (32.6) 89 (33.1)  
12-Step Programa 189 (52.8) 40 (44.9) 149 (55.4) 0.087 
Alcoholb 136 (37.9) 26 (29.2) 110 (40.9) 0.049 
Any drug useb 162 (45.1) 24 (27.0) 138 (51.3) <0.001 
Injection drug usea 65 (18.1) 9 (10.1) 56 (20.8) 0.023 
Dyadic-Level     
Main partner smokes 150 (41.0) 33 (37.08) 117 (43.5) 0.288 
Main Supporter smokes 170 (46.4) 30 (33.7) 133 (49.4) 0.010 
Family-Level     
Smokers in family 298 (83.2) 68 (76.4) 230 (85.5) 0.046 
Family encouragement to 
smoke 
30 (8.4) 6 (6.7) 24 (8.9) 0.520 
Smoking causes health 345 (96.9) 84 (95.4) 261 (97.4) 0.363 
80 
problemsc 
Family dislikes smoking 320 (89.4) 80 (89.9) 240 (89.2) 0.859 
Family has rules about 
smokingd 
313 (87.4) 79 (88.8) 234 (87.0) 0.661 
a Within the past 6 months 
b Witin the past 30 days 
c Belief held by family/friends 
















Table 3.2. Cigarette smoking characteristics of smokers living with HIV, BEACON, 
2006-2012 (n=269) 
Smoking characteristics n % 
CPDa   
<1 2 0.7 
1-10 203 75.8 
11-20 60 22.4 
21-30 1 0.4 
31+ 2 0.7 
Time to first cigarette   
<5 minutes 91 34.0 
6-30 minutes 81 30.2 
31-60 minutes 25 9.3 
60+ minute 71 26.5 
HSIb   
Low 93 34.7 
Medium 172 64.2 
High 3 1.1 
Methods used in previous 
cessation attempts  
  
Nicotine replacementc   
No 114 42.4 
Yes 155 57.6 
Pills/medicationsd   
No 246 91.4 
Yes 23 8.6 
a CPD = cigarettes per day 
b HSI = Heaviness of Smoking Index 
c Includes products like gum, Nicorette, patches, inhalers, and lozenges 









Table 3.3. Drug and alcohol use characteristics of people living with HIV, BEACON, 
2006-2012 (n=358) 
Past 30 Day Drug 










102 (28.5) 13 (14.6) 89 (33.1) 0.001 
Heroin 74 (20.7) 11 (12.4) 63 (23.4) 0.026 
Stimulantsa 3 (0.8) 0 (0.0) 3 (1.1) 0.317 
Opiatesb 47 (13.1) 8 (9.0) 39 (14.5) 0.182 
Tranquilizers/ 
barbiturates 
16 (4.5) 0 (0.0) 16 (5.9) 0.019 
Marijuana 72 (20.1) 9 (10.1) 63 (23.4) 0.007 
Hallucinogens 1 (0.3) 0 (0.0) 1 (0.4) 0.565 
Prescription drugs 12 (3.3) 2 (2.2) 10 (3.7) 0.504 
Other 3 (0.8) 0 (0.0) 3 (1.1) 0.317 
Any drug usec 162 (45.2) 24 (27.0) 138 (51.3) <0.001 
Alcohol 136 (37.9) 26 (29.2) 110 (40.9) 0.049 
a Other than cocaine/crack cocaine 
b Other than heroin 












Table 3.4. Unadjusted and adjusted odds ratios to assess the association of characteristics 
with current cigarette smoking among a sample of people living with HIV, BEACON, 
2006-2012 (n=358) 
Characteristics ORa (95% CIb) aORc,d (95% CI) 
Individual-Level   
Sex   
Male 1.0 1.0 
Female 1.28 (0.77-2.11) 1.48 (0.85-2.59) 
Age   
28-44 1.0 1.0 
45-49 0.99 (0.50-1.96) 1.23 (0.58-2.57)  
50-53 1.19 (0.58-2.45) 1.62 (0.73-3.57) 
54-65 0.62 (0.31-1.21) 1.05 (0.49-2.25) 
Race   
Black 1.0 1.0 
Non-black 2.84 (0.86-9.97) 2.96 (0.83-10.61) 
Income   
<$500 1.0 1.0 
$500+ 0.73 (0.38-1.42) 0.82 (0.40-1.66) 
Marital status   
Not married 1.0 1.0 
Married/committed 
relationship 
0.96 (0.57-1.59) 0.84 (0.46-1.54) 
CESD Score   
<16 1.0 1.0 
16+ 1.35 (0.81-2.23) 1.11 (0.64-1.93) 
12-Step Programe 1.52 (0.94-2.46) 1.74 (1.02-2.96) 
Alcoholf 1.68 (1.00-2.81) 1.27 (0.70-2.33) 
Any drug usef 2.85 (1.69-4.83) 2.90 (1.59-5.31) 
Dyadic-Level   
Main partner smokes 1.31 (0.80-2.14) 1.04 (0.56-1.93) 
Main supporter smokes 1.92 (1.17-3.17) 1.91 (1.08-3.82) 
Family-Level   
Smokers in family 1.82 (1.00-3.30) 1.20 (0.61-2.36) 
a OR = odds ratio 
b CI = confidence interval 
c aOR = adjusted odds ratio 
d Adjusted for sex, age, race, marital status, income, past 30 day alcohol use, any past 30 
day drug use, depressive symptoms, 12-step program participation, family smoking, main 
partner smoking, main supporter smoking 
e Within the past 6 months 





Table 3.5. Characteristics of main Supporter individuals, BEACON, 2006-2012 (n=229) 
Characteristic n (%) 
Sex  
Male 96 (41.9) 
Female 133 (58.1) 
  
Age (Mean (SEa)) 47.8 (0.73) 
Race  
Black 212 (92.6) 
Non-black 17 (7.4) 
Marital status  
Not married 121 (52.8) 
Married 108 (47.2) 
Income  
<$500 59 (25.9) 
$500+ 169 (74.1) 
Supporter has HIV  
No 110 (53.4) 
Yes 96 (46.6) 
Supporter lives with Index  
No 134 (58.5) 
Yes 95 (41.5) 
Dyad type  
Same-sex 82 (35.8) 
Opposite-sex 147 (64.2) 
Relationship of Supporter to Index  
Partner 99 (43.2) 
Kin 62 (27.1) 
Other 68 (29.3) 
Alcohol useb  
No 118 (51.5) 
Yes 111 (48.5) 
Any drug useb  
No 135 (59.2) 
Yes 93 (40.8) 
a SE = standard error 







4. CHAPTER 4 – QUITTING AND CUTTING DOWN ON SMOKING: 
INTEREST AMONG CIGARETTE SMOKERS LIVING WITH HIV (Aim 3) 
 
Abstract: Cigarette smoking is prevalent among people living with HIV, and is 
associated with negative health sequelae.  Most smokers with HIV report receiving 
medical advice to quit, and many are interested in quitting.  Prior research has examined 
characteristics associated with an interest in quitting, with emphasis on individual-level 
characteristics.  Research is needed to examine social-level characteristics, and 
distinguish between an interest in cessation and interest in cutting down/quitting.  Data to 
assess this aim came from a study designed to examine social environmental influences 
on current and former drug users’ HIV medication and health outcomes.  This analysis is 
comprised of 267 individuals living with HIV who are current smokers.  Fisher’s exact 
tests were used to describe the sample, and multinomial logistic regression analyses were 
used to explore associations between covariates and outcomes.  Family encouragement to 
smoke was negatively associated with interest in cutting down (aRRR=0.09, 95% 
CI=0.01-0.86) and interest in quitting (aRRR=0.27, 95% CI=0.08-0.90).  Additionally, 
participants who had made prior quit attempts were more likely to be currently interested 
in quitting smoking (aRRR=3.50, 95% CI=1.39-8.30).  Results corroborate prior findings 
that a majority of HIV-positive smokers are interested in smoking cessation.  Results 
further our knowledge by suggesting that individual- as well as social-level 
characteristics are associated with an interest in quitting smoking among smokers living 
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with HIV. Findings have implications for developing targeted smoking cessation 
























 Cigarette smoking is highly prevalent among people living with HIV (Collins et 
al., 2001; Gritz et al, 2004; Mamary et al., 2002; Burkhalter et al., 2005; Crothers et al., 
2005; Lifson et al., 2010), and is two to three times higher than what is observed in the 
general population (20%; CDC, 2011).  This disproportionately high prevalence is 
problematic when taken at face value, but especially when considering that people with 
HIV are experiencing increased life expectancies due to improved and more effective 
therapies for the treatment of HIV.  Along with increased life expectancies, an increased 
incidence of non-AIDS-related medical conditions (e.g., cardiovascular disease, bacterial 
pneumonia, chronic obstructive pulmonary disease, lung cancer) have been observed in 
this population, many of which are associated with cigarette smoking (Lewden et al., 
2005; Diaz et al., 2000; Crothers et al., 2006; Lifson et al., 2010; Miguez-Burbano et al., 
2005; Kirk et al., 2007; Chaturvedi et al., 2007; Engels et al., 2006; Petoumenos et al., 
2011; Barbaro et al., 2003; Friis-Moller et al., 2003; Savès et al., 2003).  Additionally, a 
recent study found that smokers living with HIV are now losing more life-years to 
cigarette smoking than to HIV.  Moreover, the excess mortality of smokers is tripled 
compared to non-smokers and the population-attributable risk of death associated with 
smoking is doubled among persons with HIV as compared to the general population 
(Helleberg et al., 2012). 
 Given the gravity of these health conditions and concerns, it is understandable and 
prudent that smokers with HIV are often advised against smoking.  In one study, 81% of 
current smokers living with HIV reported ever receiving medical advice to quit smoking 
in the past (Burkhalter et al., 2005), compared to 48%-70% of smokers in the general 
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population (Lucan & Katz, 2006; Doescher & Swer 2000; Denny et al., 2003).  In 
addition to receiving advice to quit, some studies indicate that a majority (63%-75%) of 
smokers living with HIV report being currently interested in quitting smoking or are 
currently thinking about quitting smoking (Mamary et al., 2002; Tesoriero et al., 2010).   
Prior research exploring the factors associated with an interest in quitting smoking 
is lacking among smokers with HIV, though some studies have been conducted among 
other underserved populations (Arnsten et al., 2004; Clarke et al., 2001; Nahvi et al., 
2006).  In extant research, a variety of factors have been found to be associated with an 
interest in quitting smoking.  For instance, among one sample of smokers living with 
HIV, greater current illegal drug use, greater levels of emotional distress, and lower 
number of prior quit attempts were associated with being less ready to quit and less 
interested in quitting smoking (Burkhalter et al., 2005).  In other marginalized 
populations—such as homeless individuals, injection drug users, and methadone 
maintenance recipients—factors such as self-efficacy for quitting, smoking-related 
symptoms like cough and shortness of breath (Arnsten et al., 2004), older age, the 
absence of alcohol abuse (Clarke et al., 2001), lower levels of nicotine dependence, and 
prior use of smoking cessation pharmacotherapy (Nahvi et al., 2006) have been found to 
be associated with an interest in quitting smoking. 
 Despite the aforementioned research, several gaps in the literature are apparent.  
First, relatively little research has focused on HIV-positive smokers overall; even less has 
explored factors that are associated with an interest in quitting smoking.  Also, in 
previous work, among both people with HIV and other marginalized populations, the 
focus has been placed on individual-level characteristics such as age and prior quit 
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attempts, to the exclusion of social-level factors, which have been shown to be associated 
with other behaviors like illegal drug use as well as HIV and psychiatric medication 
adherence (Bohnert et al., 2009; Knowlton et al., 2006; Magura et al., 2011), and thus 
may also influence an interest in quitting smoking.  Furthermore, previous research has 
not made a distinction between individuals having an interest in quitting smoking versus 
having an interest in cutting down on smoking.   
 In light of these gaps in the literature, the aim of the present study was to explore 
and compare individual- and social-level factors associated with an interest in cutting 
down on cigarette smoking as well as an interest in quitting cigarette smoking among a 
sample of cigarette smokers living with HIV.  An additional aim was to describe the 
types of smoking cessation interventions that current cigarette smokers were interested in 
utilizing.  Two conceptual frameworks guided these analyses: The Ecological Model for 
Health Promotion (McLeroy et al., 1988) and Social Cognitive Theory (Bandura, 1986).  
Both of these theories state that individual behavior is influenced by personal (i.e., 
individual-level) and environmental (i.e., social-level) factors.  As a result, it was 
hypothesized that individual-level characteristics, such as prior quit attempts, and social-
level characteristics, such as family encouragement to quit smoking, would be associated 
with both an interest in cutting down on and an interest in quitting cigarette smoking. 
 
4.2 Methods 
4.2.1 Data Source 
 Data for this dissertation aim came from the BEACON (BEing Active & 
CONnected) Study.  BEACON is a longitudinal study comprised of three visits 
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conducted at 6-month intervals.  Data were collected between the years 2006-2012 in 
Baltimore, Maryland, US.  The study allowed for the enrollment of two types of 
participants: Index and Supporter participants.  Index participants were recruited from 
clinic-based venues, such as the Johns Hopkins University Moore Clinic for HIV care, as 
well as via targeted street outreach and were considered to be eligible if they were HIV-
positive, 18 years of age or older, current/former injection drug users, and on HIV 
treatment at the time of study enrollment.  Being “on HIV treatment” was defined as 
having taken at least one HIV treatment medication at least one time during the past 30 
days.  Index participants were also asked to designate a main Supporter (i.e., a main 
supportive tie who provides the Index with emotional support and instrumental assistance 
in living with their HIV diagnosis), whom, with permission from the Index participant, 
was invited to participate in the study as well.  Eligibility criteria for Supporter 
participants is as follows: 18 years of age or older, know that their Index has HIV, and 
verification that they were not professionals whose only relationship with the Index was 
in the capacity of service provider.  All data were collected by trained interviewers and 
via audio computer-assisted self-interviewing (ACASI). Index and Supporter dyads were 
administered questionnaires at similar time points.  Information regarding the 
characteristics of Index and Supporter participants was self-reported by the Indexes and 
Supporters, respectively.   
 Questionnaires for the three semi-annual visits gathered information on a variety 
of topics, including medication adherence, illegal drug use, and mental health variables.  
The questionnaire used at the 6-month follow-up visit contained the most information 
regarding cigarette smoking as compared to either the baseline or 12-month follow-up 
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visits.  Because of the present study’s focus on smoking behaviors, we utilized data from 
the 6-month visit.  The sample size at the 6-month visit was 358 Index participants.  The 
sample was further reduced to include only current cigarette smokers who provided 
information on interest in cutting down on or quitting smoking, leaving a final sample of 
267 for the present analyses.  The Johns Hopkins University Bloomberg School of Public 
Health Institutional Review Board approved this study.   
4.2.2 Measures 
4.2.2.1 Individual-level variables 
Sociodemographic variables - Sex was dichotomized (male/female), and age was 
categorized into approximate quartiles (28-44; 45-49; 50-53; 54-65).  Race was 
dichotomized as “Black” or “non-Black” due to the sample distribution.  Past month 
income from all sources (including food stamps) and marital status were dichotomized 
(<$500 versus >$500; “not married” versus “married or in a committed relationship”, 
respectively). 
Drug and alcohol use – Data from participants were dichotomized based on self-
reported use of alcohol and extramedical use of a variety of illegal substances (i.e., 
stimulants, opiates, tranquilizers or barbiturates, marijuana, heroin, cocaine or crack, 
hallucinogens, prescription drugs, and “other drugs”) within the past month.  A 
dichotomous composite variable was created for “any past month drug use”, excluding 
alcohol.  A dichotomous variable was also created based on self-reported injection drug 
use in the past 6 months. 
Depressive symptoms – The Center for Epidemiologic Studies Depression Scale 
(CES-D), a short (20 item) self-report scale (Radloff, 1977), was used to assess 
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depressive symptoms.  Possible scores range from 0 to 60, with higher scores indicating 
the presence of greater symptomatology.  A score of 16 or higher identifies individuals 
with clinically meaningful depressive symptoms (Radloff, 1977).  In terms of 
psychometric properties, the CES-D has been shown to have very good internal 
consistency reliability (>0.85) and acceptable test-retest reliability (Radloff, 1977; Hann 
et al., 1999).  Additionally, it has moderate-good (0.44-0.75) concurrent validity (Radloff, 
1977), good discriminant validity (Weissman, 1977), and sensitivity of 0.95 and 
specificity of 0.70 when compared to the Diagnostic Interview Schedule for DSM-IV 
(Thomas et al., 2001).  In addition to having good psychometric properties, the CES-D 
has been shown to be of utility among samples similar to the one utilized for the present 
work: low socioeconomic status, primarily African American (Thomas et al., 2001), 
urban substance using samples (Yang et al., 2013; Latkin et al., 2012). 
HIV primary care visits & drug treatment utilization – The number of HIV 
primary care visits in the past 6 months was categorized as approximate tertiles (0-2; 3-4; 
5+).  Utilization of 12-step programs in the past 6 months was dichotomized (yes/no). 
Cigarette smoking – All participants were asked whether they had smoked 
cigarettes in the past 30 days.  A dichotomous variable (yes/no) was created based on the 
responses, and those individuals reporting past 30 day smoking were considered to be 
current smokers and were administered additional smoking-related questions.  Smokers 
were asked about how soon they smoke their first cigarette upon waking (i.e., time to first 
cigarette; TTFC) (<5 minutes, 6-30 minutes, 31-60 minutes, and 60+ minutes), the 
number of cigarettes that they smoke per day (i.e., cigarettes per day; CPD) (<1, 1-10, 11-
20, 21+), as well as about prior use of nicotine replacement therapy (NRT; yes/no) or 
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medications/pills for the purpose of smoking cessation (yes/no).  The latter two variables 
were combined to create a single dichotomous variable assessing past use of either NRT 
or medications/pills for smoking cessation (yes/no). 
Additionally, using the CPD and TTFC questions, the Heaviness of Smoking 
Index (HSI; Heatherton et al., 1989) was created.  The HSI is a measure of nicotine 
dependence, with scores ranging from 0-6, with higher scores indicating a higher level of 
nicotine dependence.  The HSI was conceptualized as a categorical variable with 3 levels: 
low (0-1), medium (2-4), and high (5-6) dependence, consistent with prior research 
(Chaiton et al., 2007).  However, based on the distribution of responses from the present 
sample, a dichotomous variable was used in the analyses (i.e., low versus medium-high 
dependence).  When examining the measure’s psychometric properties, the HSI has been 
shown to have good test-retest (0.72) reliability over a 3-year period (Borland, 2010), 
good sensitivity (0.79) and specificity (0.96), and good concordance (Cohen’s 
kappa=0.74) with the Fagerström Test for Nicotine Dependence (Heatherton et al., 1989), 
the most widely used measure of nicotine dependence (Chabrol et al., 2005). 
4.2.2.2 Dyadic-level variables 
Based on Index participants’ responses to a question asking if their main partner 
currently smoked, a dichotomous variable (yes/no) was created.  Additionally, based on 
Supporters’ responses to a question asking if they currently smoked, an additional 
dichotomous variable (yes/no) was created.  Supporters who endorsed current smoking 
were also questioned as to whether they had previously used NRT or medications/pills 
for smoking cessation, or if they were currently interested in quitting smoking; 
dichotomous variables were created based on responses to both of these questions 
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(yes/no).   
However, not all Index participants reported having a main partner or had a main 
Supporter join the study: 145 (54%) reported having a main partner, and 169 (63%) of 
Index participants had a main Supporter who joined the study.  In order to make use of 
the full sample (n=267), the two dyadic-level variables were coded as “0” (i.e., “no”) for 
individuals without partners or Supporters.  This was deemed reasonable, since Index 
participants without main partners or Supporters would not have had the influence of 
cigarette smoking by partners or Supporters at that point in their lives.  Moreover, 
sensitivity analyses were performed that helped to justify this decision. 
4.2.2.3 Family-level variables 
  Index participants were questioned on the following topics: the prevalence of 
smoking among family members; encouragement to smoke by family members; 
encouragement to quit smoking by family members; family members’ belief that 
smoking causes health problems; whether family members dislike cigarette smoking; and 
whether family members have rules regarding where someone can or cannot smoke 
within their homes.  Dichotomous (yes/no) variables were created based on Index 
participants’ responses to these questions. 
4.2.3 Statistical Analysis 
Fisher’s exact tests were used to assess the statistical significance of relationships 
between an interest in cutting down on smoking, quitting smoking, and no interest in 
either cutting down on or quitting smoking with individual-level, dyadic-level, and 
family-level variables.  Unadjusted and adjusted logistic regression analyses were used to 
calculate relative risk ratios (RRRs), adjusted relative risk ratios (aRRRs), and 
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corresponding 95% confidence intervals (CI).  Variable selection for the adjusted model 
was based on a combination of evidence from the prior literature, a priori theory, and 
Fisher’s exact p-values of <0.05.  Variables selected for the adjusted model included: sex, 
age, race, income, marital status, past 30 day drug use, family encouragement to smoke, 
nicotine dependence, prior cessation attempts using pharmacologic smoking cessation 
aids, main partner smoking, main Supporter smoking, and main Supporter’s interest in 
quitting smoking.   
 A final sample of 267 current smokers who had provided information regarding 
having an interest in cutting down on or quitting smoking was retained for the adjusted 
analyses.  Additional sensitivity analyses were also performed among only those current 
smokers who had a main Supporter (n=169) in an effort to assess how the decision to 
code the two dyadic-level variable for Supporter smoking status as “0” (i.e., “no”) for 
individuals without Supporters affected results.  All analyses were performed using 
STATA SE statistical software version 12.0 (StataCorp, 2011). 
 
4.3 RESULTS 
4.3.1 Participant characteristics 
 Characteristics of this sample of smokers with HIV can be found in Table 4.1.  
Nearly three-quarters of the sample (74%) reported being interested in quitting smoking 
and an additional 15% were interested in cutting down on smoking.  The remaining 11% 
reported no interest in either quitting or cutting down on smoking.  Sixty percent of the 
sample was male, 24.7% were between the ages of 28-44, 27.7% between the ages of 45-
49, 26.2% between the ages of 50-53, and 21.4% of the sample was between the ages of 
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54-65.  The majority of the sample was black (90.6%), reported a monthly income of 
$500 or greater (81.7%), were unmarried (68.2%), and did not meet criteria for clinically 
meaningful depressive symptomatology as identified by the CESD (61.0%).  Forty-two 
percent of participants reported making between 0-2 HIV primary care visits in the past 6 
months, while 24.7% and 33.0% reported making 3-4 and 5-30 visits, respectively.  
Approximately half of participants reported engaging in 12-step programs in the past 6 
months (55.8%) as well as past month drug use (50.9%).  Forty-one percent of the sample 
reported past month alcohol use.  Nearly 60% of the sample reported having made prior 
cessation attempts using pharmacologic smoking cessation aids, with those interested in 
quitting (64.3%) and those interested in cutting down (56.4%) being more likely to report 
past cessation attempts than those who are not currently interested in quitting or cutting 
down (31.0%).    
 Forty-four percent of the sample reported having a main partner who also smokes, 
while 49.4% had a main Supporter who was a current smoker.  Approximately 37% of 
the sample had a main Supporter who was currently interested in quitting smoking, and 
24.5% had a main Supporter who reported having made prior cessation attempts using 
pharmacologic smoking cessation aids.   
 A majority of Indexes reported that their family and/or friends smoked (85.4%), 
their family believed that smoking causes health problems (97.4%), dislike smoking 
(89.1%), have rules about where one can and cannot smoke in their homes (86.9%), and 
encourage the Index participant to quit smoking (85.1%).  However, a few participants 
reported that their family encourages them to smoke (8.2%), though individuals who 
were not interested in quitting or cutting down (20.7%) were more likely than either those 
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who were interested in cutting down on (2.6%) or quitting smoking (7.5%) to report 
having family members who encourage them to smoke (p=0.029). 
4.3.2 Smoking characteristics 
Cigarette smoking characteristics are shown in Table 4.2.  Most smokers (75.7%) 
reported smoking 1-10 cigarettes per day (CPD), and approximately one-third reported 
smoking their first cigarette of the day within 5 minutes of waking (33.7%).  More than 
half (64.1%) of the current smokers exhibited a medium-level of nicotine dependence, as 
assessed by the HSI.  Fifty-seven percent of smokers reported previous experience with 
nicotine replacement therapy, and 8.6% reported previously using pills or medication for 
smoking cessation, for a combined total of 59.6% of participants with prior experience 
using pharmacologic smoking cessation aids.  Significant differences were found 
between individuals with varying levels of interest in modifying their smoking behaviors; 
individuals interested in quitting reported the greatest prior use of NRT or medications 
for cessation (64.3%), followed by individuals interested in cutting down on smoking 
(56.4%), and individuals not interested in cutting down or quitting smoking (31.0%) χ2 (1, 
N = 267) = 11.83, p = 0.003. 
4.3.3 Drug use 
 Detailed information on drug use can be found in Table 4.3.  Approximately half 
(51%) of the sample reported any drug use in the past 30 days.  The most commonly used 
substances within the past month were cocaine/crack cocaine (33.0%), heroin (23.2%), 
marijuana (23.2%), and other opiates (14.2%).  Significant differences were found on the 
basis of past month heroin use between individuals interested in cutting down (23.1%), 
quitting (20.6%), and those with no interest in quitting or cutting down (41.4%) (χ2 (1, N 
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= 267) = 6.13, p = 0.047).  Smaller proportions of the sample reported other drug use: 
other stimulants (1.1%), tranquilizers/barbiturates (6.0%), hallucinogens (0.4%), and 
prescription drugs (3.7%). 
4.3.4 Interest in smoking cessation modalities 
 Information regarding interest in various smoking cessation modalities can be 
found in Table 4.4.  Of the 267 persons in this sample, 238 (89.1%) expressed an interest 
in either cutting down on (n = 29; 11%) or quitting smoking (n = 199; 74%).  Of those 
who had not previously utilized NRT and were interested in quitting or cutting down 
(n=92), 36.9% indicated that they might be interested in trying NRT and an additional 
33.7% said that they would be interested in trying NRT.  Similarly, of those who had not 
previously utilized pills/medications for smoking cessation and were interested in either 
quitting or cutting down (n=217), 33.6% might be interested in trying pills/medications 
and an additional 29.1% were interested in trying pills/medications.  A majority of 
participants reported an interest in participating in a smoking cessation intervention with 
a family member (67.6%), a friend (71.7%), with a main partner (73.6%), in a group 
setting (76.4%), or in a group setting with someone that they know (88.9%) 
4.3.5 Multinomial logistic regression analyses 
 Information on associations between interest in cutting down on smoking and the 
covariates is presented in Table 4.5.  In adjusted analyses, only one association remained 
statistically significant.  Participants who received encouragement to smoke from their 
family members were significantly less likely than those who did not to be interested in 
cutting down on smoking (aRRR=0.09, 95% CI=0.01-0.86).  Despite not achieving 
statistical significance, strong positive associations with an interest in cutting down were 
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found for two additional factors: having a main partner who is a smoker (aRRR=2.20, 
95% CI=0.67-7.25) and having a main Supporter who is interested in quitting smoking 
(aRRR=2.55, 95% CI=0.51-12.77).  
 Information on associations between interest in quitting smoking and various 
covariates is presented in Table 4.5.  After controlling for covariates in the adjusted 
model, family encouragement to smoke remained significantly associated with an interest 
in quitting smoking: Participants who received encouragement to smoke from family 
members were significantly less likely than those who did not to be interested in quitting 
smoking (aRRR=0.27, 95% CI=0.08-0.90).  Additionally, individuals who had made 
prior quit attempts using NRT or medications were significantly more likely than those 
who had not made prior quit attempts using such pharmacotherapies to be currently 
interested in quitting smoking in the adjusted model (aRRR=3.50, 95% CI=1.39-8.30).  
Furthermore, though not achieving statistical significance in adjusted analyses, several 
other factors had strong associations with having an interest in quitting smoking.  For 
instance, older age (45-49: aRRR=2.53, 95% CI=0.81-7.92; 50-53: aRRR=2.23, 95% 
CI=0.68-7.30; 54-65: aRRR=4.14, 95% CI=0.96-17.94) was positively associated with an 
interest in quitting smoking.  Additionally, having a main Supporter who was interested 
in quitting (aRRR=2.38, 95% CI=0.58-9.77) was associated with having an interest in 
quitting.  
4.3.6 Sensitivity analyses 
 In adjusted analyses, when restricting the sample to smokers who had a main 
Supporter (n=169), main findings did not differ markedly from findings from analyses 
utilizing the full sample (n=267).  Participants who received encouragement to smoke 
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from their family members were significantly less likely than those who did not to be 
interested in cutting down on smoking (aOR=0.06, 95% CI=0.01-0.81).  Additionally, 
participants who received encouragement to smoke from family members were 
significantly less likely than those who did not to be interested in quitting smoking  
(aOR=0.09, 95% CI=0.01-0.60).  Participants who had made prior quit attempts using 
NRT or medications were significantly more likely than those who had not made prior 
quit attempts using such pharmacotherapies to be currently interested in quitting smoking 
(aOR=6.24, 95% CI=1.42-27.39).  No discrepant findings between the full and restricted 
samples were observed. 
 
4.4 DISCUSSION 
 Findings from this study identified individual- and social-level characteristics 
associated with an interest in cutting down on as well as an interest in quitting smoking 
among a sample of cigarette smokers living with HIV.  Specifically, prior use of 
pharmacologic smoking cessation aids was positively associated with having a current 
interest in quitting smoking.  This finding, in addition to being congruent with prior 
research (Nahvi et al., 2006), is perhaps not all that surprising.  Given that, among the 
general population, actual quit attempts are frequently found to be associated with prior 
quit attempts (Zhou et al., 2009; Hagimoto et al., 2009; Vangeli et al., 2011), and that it 
would logically follow that quit attempts are associated with an interest in quitting, one 
could fairly easily extrapolate that past quit attempts would also be associated with 
interest in quitting.  Additionally, prior research (Clarke et al., 2001) has found older age 
to be positively associated with interest in quitting smoking.  Though not achieving 
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statistical significance in this sample, when comparing individuals age 54-65 to the 
youngest age group (28-44) a trend for significance was observed when examining an 
interest in quitting smoking (p=0.057).  Failure to achieve significance may be the result 
of limited power due to a relatively small sample size (n=267).  In terms of social-level 
factors, a novel finding included having family members who encourage smoking was 
significantly negatively associated with having an interest in cutting down on smoking as 
well as having an interest in quitting smoking.  Additionally, though not achieving 
significance in adjusted models, strong associations were found between other social-
level factors and interest in cutting down on or quitting smoking: strong, albeit 
statistically non-significant, associations were found between persons with a main partner 
who smokes, as well as persons with a Supporter who is interested in quitting and having 
an interest in cutting down on smoking.  Additionally, strong associations were found 
between having a Supporter who is interested in quitting and having an interest in 
quitting smoking.   Similar to the age findings discussed above, failure of these social-
level characteristics to achieve statistical significance may be due to limited power. 
It is possible that vastly different characteristics associated with the two outcomes 
were not observed due to the similar nature of both outcomes: both were concerned with 
reduction in cigarette smoking.  Additionally, findings from sensitivity analyses, whereby 
the sample was restricted to only those individuals who had a Supporter, yielded no 
overall differences from analyses utilizing the full sample.  The lack of differences 
between the full and restricted samples helps to justify the decision to utilize the full 
sample in the interest of increasing statistical power. 
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In addition to findings from the adjusted model, participants expressed interest in 
a variety of smoking cessation modalities.  Though interest was expressed for most 
modalities, interventions involving a social component received particularly high 
endorsement.  Nearly 70% of smokers reported that they would be interested 
participating in interventions with a family member, and more than 70% were in favor of 
interventions taking place with a friend, main partner, in a group setting, or in a group 
setting with someone that the smoker knows.  These findings are similar to those reported 
by Mamary and colleagues (2002), who found that 69% of smokers sampled at an HIV 
clinic were interested in participating in group-based smoking cessation programs.  These 
reported interests, coupled with the finding from this study that receiving encouragement 
to smoke from family members is associated with a decreased interest in quitting or 
cutting down underscores the importance of social factors in association with smoking 
behaviors among cigarette smokers with HIV. 
Several limitations should be acknowledged.  First, all data were collected via 
self-report, which creates the possibility for social desirability bias.  To reduce the 
possibility for this type of bias, data were collected using audio computer-assisted self-
interviewing (ACASI), which has been shown to improve the likelihood of honest 
reporting of sensitive information (Macalino et al., 2002).  Second, data were cross-
sectional and observational; therefore causal relationships between variables cannot be 
inferred. Third, the survey also assessed interest in cutting down on smoking or quitting 
smoking with two questions, without assessing degree of interest in cutting 
down/quitting, or intentions to cut down/quit within a specified time period.  Fourth, the 
survey does not contain sociometric social network data (i.e., data in which the entire 
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community, or as many as possible, are interviewed, and all respondents are asked about 
their contacts within the community) (Wasserman & Faust, 1994).  With sociometric 
data, one might be able to obtain additional information, including the density of smoking 
in the network, the role relationship of smokers, and the specific support provided by 
smokers. Finally, some of the subgroup sample sizes were relatively small, with reduced 
power.   Despite this, to our knowledge, this study represents one of the only studies to 
assess social-level characteristics in an HIV-positive population.   
Notwithstanding the aforementioned limitations, this study possesses several 
strengths that merit acknowledgement.  Results from these analyses make a contribution 
to the body of literature concerning characteristics that are associated with cigarette 
smoking behaviors, specifically interest in quitting or cutting down on smoking, among 
people with HIV—a population exhibiting an unduly high prevalence of cigarette 
smoking and, consequently, bearing a disproportionate burden of smoking-related 
morbidity.  The majority of existing research regarding cigarette smoking and HIV has 
focused on exploring the characteristics associated with current smoking status, while the 
present study has focused on a cigarette smoking behavior about which not much is 
known in this population: current interest in quitting or cutting down on smoking.  
Additionally, the present study extends the literature by investigating social 
environmental variables associated with smoking in addition to individual-level 
characteristics.  This study focuses on and provides information on a typically hard-to-
reach population among which cigarette smoking is a significant public health concern. 
In summary, findings from the present study corroborate previous research 
findings showing that individual level-factors, like prior smoking cessation attempts, are 
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associated with an interest in quitting smoking among smokers living with HIV.  
Additionally, findings from this study extend existing knowledge by demonstrating that 
social-level factors, specifically that encouragement to smoke by family members, are 
associated with a decreased interest in cutting down on or quitting smoking.  These 
findings are significant in that they contribute to an increased understanding of the factors 
that are related to smoking behaviors among a high-risk population.  Furthermore, they 
have potential implications for the development of smoking cessation treatment 
interventions.  Given the high prevalence of smoking among persons with HIV, it may be 
prudent to integrate smoking cessation efforts with HIV primary care settings.  Findings 
from this study also emphasize that members of an individual’s social network, namely 
family members, may strongly influence their smoking behaviors.  Based on findings 
from adjusted models, as well as self-reported interest in various smoking cessation 
modalities, smoking cessation interventions with a social component, such as ones that 
involve family or other network members, may prove to be effective and should be 
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Table 4.1. Characteristics of cigarette smokers living with HIV, stratified by interest in cutting down or quitting smoking, 
BEACON, 2006-2012 (n=267) 
Characteristic Total Sample 
(n=267) 










 n (%) n (%) n (%) n (%)  
Individual-Level      
Sex      
Male 161 (60.3) 17 (58.6) 22 (56.4) 122 (61.3) 0.799 
Female 106 (39.7) 12 (41.4) 17 (43.6) 77 (38.7)  
Age      
28-44 66 (24.7) 13 (44.8) 14 (35.9) 39 (19.6) 0.013 
45-49 74 (27.7) 7 (24.1) 11 (28.2) 56 (28.1)  
50-53 70 (26.2) 6 (20.7) 11 (28.2) 53 (26.6)   
54-65 57 (21.4) 3 (10.4) 3 (7.7) 51 (25.6)  
Race      
Black 242 (90.6) 26 (89.7) 36 (92.3) 180 (90.4) 1.000 
Non-black 25 (9.4) 3 (10.3) 3 (7.7) 19 (9.6)  
Income      
<$500 49 (18.3) 5 (17.2) 6 (15.4) 38 (19.1) 0.899 
$500+ 218 (81.7) 24 (82.8) 33 (84.6) 161 (80.9)  
Marital status      
Not married 182 (68.2) 18 (62.1) 23 (59.0) 141 (70.8) 0.252 
Married/committed 
relationship 
85 (31.8) 11 (37.9) 16 (41.0) 58 (29.2)  
CESDa      
<16 163 (61.0) 19 (65.5) 24 (61.5) 120 (60.3) 0.873 
16+ 104 (39.0) 10 (34.5) 15 (38.5) 79 (39.7)  
HIV primary care 
visitsb 
     
0-2 113 (42.3) 13 (44.8) 20 (51.3) 80 (40.2) 0.355 
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3-4 66 (24.7) 4 (13.8) 10 (25.6) 52 (26.1)  
5-30 88 (33.0) 12 (41.4) 9 (23.1) 67 (33.7)  
12-Step program 
participationb 
149 (55.8) 15 (51.7) 26 (66.7) 108 (54.3) 0.332 
Drug usec 136 (50.9) 19 (65.5) 23 (59.0) 94 (47.2) 0.105 
Alcohol usec 110 (41.2) 12 (41.4) 20 (51.3) 78 (39.2) 0.381 
Prior quit attemptsd 159 (59.5) 9 (31.0) 22 (56.4) 128 (64.3) 0.003 
Dyadic-Level      
Main partner smokes 117 (43.8) 12 (41.4) 24 (61.5) 81 (40.7) 0.054 
Main Supporter 
smokes 
132 (49.4) 11 (37.9) 24 (61.5) 97 (48.7) 0.149 
Main Supporter 
interested in quitting 
smoking 
99 (37.1) 5 (17.2) 18 (46.1) 76 (38.2) 0.041 
Main Supporter made 
quit attempts in pastd 
65 (24.3) 5 (17.2) 14 (35.9) 46 (23.1) 0.160 
Family-Level      
Family encouragement 
to smoke (yes) 
22 (8.2) 6 (20.7) 1 (2.6) 15 (7.5) 0.029 
Smoking causes health 
problemse 
259 (97.4) 27 (96.4) 39 (100.0) 193 (97.0) 0.663 
Family dislikes 
smoking 
238 (89.1) 26 (89.7) 34 (87.2) 178 (89.4) 0.945 
Family rules about 
smokingf 
232 (86.9) 24 (82.8) 35 (89.7) 173 (86.9) 0.717 
a CESD = Centers for Epidemiological Studies Depression scale 
b Within the past 6 months 
c Within the past 30 days 
d Quit attempts using nicotine replacement therapy or pills/medications 
e Belief held by family/friends 
f Rules about where people can and cannot smoke in the home 
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Table 4.2. Smoking characteristics of current cigarette smokers living with HIV, BEACON, 2006-2012 (n=267) 
Characteristic Total Sample 
(n=267) 
No interest in 
cessation 
(n=29) 
Interested in cutting 
down 
(n=39) 
Interested in quitting 
(n=199) 
p-value 
 n (%) n (%) n (%) n (%)  
Cigarettes per day      
<1 2 (0.7) 0  0 2 (1.0) 0.074 
1-10 202 (75.7) 18 (62.1) 26 (66.7) 158 (79.4)  
11-20 60 (22.5) 11 (37.9) 12 (30.8) 37 (18.6)  
21-30 1 (0.4) 0 1 (2.6) 0  
31+ 2 (0.7) 0 0 2 (1.0)  
Time to first cigarette      
<5 minutes 90 (33.7) 13 (44.8) 12 (30.8) 65 (32.7) 0.224 
6-30 minutes 81 (30.3) 7 (24.1) 18 (14.1) 56 (28.1)  
31-60 minutes 25 (9.4) 3 (10.3) 3 (7.7) 19 (9.5)  
60+ minute 71 (26.6) 6 (20.7) 6 (15.4) 59 (29.6)  
Nicotine dependencea       
Low 93 (34.8) 9 (31.0) 9 (23.1) 75 (37.7) 0.380 
Medium 171 (64.1) 20 (69.0) 29 (74.4) 122 (61.3)  
High 3 (1.1) 0 (1 (2.5) 2 (1.0)  
Prior use of NRTb 155 (57.7) 9 (31.0) 20 (51.3) 125 (62.8) 0.004 
Prior use of pills/medications 
for cessation c 
23 (8.6) 2 (6.9) 4 (10.3) 17 (8.5) 0.885 
Prior use of any cessation aidsd 159 (59.6) 9 (31.0) 22 (56.4) 128 (64.3) 0.003 
a According to the Heaviness of Smoking Index  
b Includes products like nicotine gum, nicotine patches, inhalers, or lozenges 
c Includes products for reducing cigarette cravings, like Zyban, Wellbutrin, or Chantix (Bupropion or Varenicline) 
d Use of either nicotine replacement therapy or pills/medications 
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Table 4.3. Interest in various smoking cessation methods among current smokers living 
with HIV who are currently interested in cutting down on or quitting smoking, 
BEACON, 2006-2012 (n=238) 
Smoking Cessation Method n % 
Nicotine replacementa,b   
No 27 29.4 
Maybe 34 36.9 
Yes 31 33.7 
Pills/medicinec,d   
No 81 37.3 
Maybe 73 33.6 
Yes 63 29.1 
With a family member   
No 77 32.4 
Yes 161 67.6 
With a friend   
No 67 28.3 
Yes 170 71.7 
With main partner   
No 37 26.4 
Yes 103 73.6 
In a group   
No 56 23.6 
Yes 181 76.4 
Group + someone you know   
No 20 11.1 
Yes 161 88.9 
a Includes products like nicotine gum, nicotine patches, inhalers, or lozenges 
b Among those who were interested in quitting/cutting down on smoking and had not 
tried nicotine replacement methods in the past 
c Includes products for reducing cigarette cravings, like Zyban, Wellbutrin, or Chantix 
(Bupropion or Varenicline) 
dAmong those who were interested in quitting/cutting down on smoking and had not tried 







Table 4.4. Drug and alcohol use characteristics of cigarette smokers living with HIV, 
BEACON, 2006-2012 (n=267) 
Past 30 Day 
Drug Use 












88 (33.0) 13 (44.8) 17 (43.6) 58 (29.1) 0.076 
Heroin 62 (23.2) 12 (41.4) 9 (23.1) 41 (20.6) 0.047 
Stimulantsa 3 (1.1) 0 (0.0) 1 (2.6) 2 (1.0) 0.582 
Opiatesb 38 (14.2) 2 (6.9) 7 (17.9) 29 (14.6) 0.419 
Tranquilizers/ 
barbiturates 
16 (6.0) 2 (6.9) 2 (5.1) 12 (6.0) 0.954 
Marijuana 62 (23.2) 10 (34.5) 6 (15.4) 46 (23.1) 0.182 
Hallucinogens 1 (0.4) 1 (3.4) 0 (0.0) 0 (0.0) 0.016 
Prescription 
drugs 
10 (3.7) 1 (3.4) 2 (5.1) 7 (3.5) 0.886 
Other 3 (1.1) 0 (0.0) 0 (0.0) 3 (1.51) 0.595 
Any drug use 136 (50.9) 19 (65.5) 23 (59.0) 94 (47.2) 0.102 
Alcohol 110 (41.2) 12 (41.4) 20 (51.3) 78 (39.2) 0.374 
a Other than cocaine/crack cocaine 
b Other than heroin 
117 
Table 4.5. Unadjusted and adjusted multinomial logistic regression analyses for characteristics that are associated with an 
interest in quitting smoking and an interest in cutting down on smoking, as compared to no interest in quitting or cutting down 
among current cigarette smokers living with HIV, BEACON, 2006-2012 (n=267) 
 Interest in cutting 
down vs. no interest 
Interest in cutting 
down vs. no interest 
Interest in quitting 
vs. no interest 
Interest in quitting 
vs. no interest 
Characteristic RRRa (95% CIb) aRRRc,d (95% CIb) RRRa (95% CIb) aRRRc,d (95% CIb) 
Individual-Level     
Sex     
Male 1.0 1.0 1.0 1.0 
Female 1.09 (0.41-2.90) 0.89 (0.30-2.68) 0.91 (0.30-2.72) 0.98 (0.39-2.47) 
Age     
28-44 1.0 1.0 1.0 1.0 
45-49 1.46 (0.43-4.90) 1.74 (0.44-6.80) 1.78 (0.45-7.00) 2.53 (0.81-7.92) 
50-53 1.70 (0.49-5.93) 1.36 (0.33-5.57) 1.47 (0.36-6.04) 2.23 (0.68-7.30) 
54-65 0.93 (0.16-5.45) 0.76 (0.11-5.25) 0.90 (0.13-6.26) 4.14 (0.96-17.94) 
Race     
Black 1.0 1.0 1.0 1.0 
Non-black 0.72 (0.13-3.87) 0.42 (0.07-2.63) 0.42 (0.07-2.64) 0.73 (0.17-3.07) 
Income     
<$500 1.0 1.0 1.0 1.0 
$500+ 1.14 (0.31-4.20) 1.26 (0.31-5.20) 1.12 (0.28-4.53) 0.84 (0.27-2.65) 
Marital status     
Not married 1.0 1.0 1.0 1.0 
Married/committed 
relationship 
1.14 (0.42-3.05) 0.63 (0.19-2.03) 0.61 (0.19-1.99) 0.57 (0.27-2.65) 
Drug usee,f 0.76 (0.28-2.05) 0.78 (0.27-2.27) 0.76 (0.26-2.21) 0.54 (0.22-1.31) 
Prior quit attemptsg 2.87 (1.05-7.89) 2.66 (0.88-8.07) 2.90 (0.96-8.80) 3.50 (1.39-8.80) 
Nicotine dependenceh     
Low 1.0 1.0 1.0 1.0 
Medium-High 1.50 (0.51-4.43) 1.37 (0.42-4.39) 1.33 (0.41-4.23) 0.71 (0.28-1.82) 
Dyadic-Level     
Main partner smoking 2.27 (0.85-6.04) 2.20 (0.67-7.25) 2.24 (0.69-7.35) 1.23 (0.45-3.34) 




interested in quitting 
smoking 
4.11 (1.30-13.01) 2.55 (0.51-12.77) 2.96 (1.08-8.10) 2.38 (0.58-9.77) 
Family-Level     
Family encouragement 
to smoke 
0.10 (0.01-0.89) 0.09 (0.01-0.86) 0.08 (0.01-0.82) 0.27 (0.08-0.90) 
a RRR = relative risk ratio 
b aRRR = adjusted relative risk ratio 
c CI = confidence interval 
d  Multivariate model adjusted for sex, age, race, income, marital status, drug use, family encouragement to smoke, nicotine 
dependence, prior cessation attempts, main partner smoking, main Supporter smoking, main Supporter’s interest in quitting 
e Not including alcohol 
f Within the past 30 days 
g Quit attempts using nicotine replacement therapy or pills/medications 
h Nicotine dependence according to the Heaviness of Smoking Index 
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5. CHAPTER 5 – PRIOR SMOKING CESSATION ATTEMPTS USING 
NICOTINE REPLACEMENT OR MEDICATION THERAPIES: ASSOCIATIONS 
WITH INDIVIDUAL AND SOCIAL CHARACTERISTICS AMONG SMOKERS 
LIVING WITH HIV (Aim 4) 
 
Abstract: Cigarette smoking is highly prevalent among people living with HIV, and is 
associated with an elevated risk of a variety of negative health outcomes, including death.  
Little research exists to explore characteristics associated with smoking behaviors, such 
as past quit attempts, among smokers living with HIV.  Moreover, the little research that 
does exist has focused on individual-level characteristics, to the neglect of social 
environmental characteristics.  We aimed to explore individual- and social-level 
characteristics associated with prior use of nicotine replacement (NRT) or medications 
for smoking cessation.  Data to assess this aim came from 269 current smokers on 
antiretroviral therapy interviewed in a study on informal caregiving conducted in 
Baltimore, Maryland.  Logistic regression analyses were used to examine associations 
between individual- and social-level characteristics with prior use of NRT or medications 
for smoking cessation.  Approximately half (51.3%) of participants reported current drug 
use.  Older age (45-49: adjusted odds ratio (aOR)=3.44, 95% confidence interval 
(CI)=1.60-7.39; 54-65: aOR=2.74, 95% CI=1.22-6.17), non-Black race (aOR=3.61, 95% 
CI=1.23-10.62), and having a main Supporter who has used NRT or medications for 
cessation in the past (aOR=2.40, 95% CI=1.24-4.63) were positively associated with an 
increased likelihood of prior use of NRT or medications for smoking cessation. Findings 
corroborate prior research concerning individual-level characteristics, and also reveal the 
importance of social-level characteristics in association with prior use of NRT or 
medications for cessation.  These findings have implications for the development and 
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 Despite the fact that the prevalence of cigarette smoking has been on the decline 
among the United States (US) general population since the 1960’s (CDC, 2012) and is 
currently approximately 19% (CDC, 2011a), smoking is still highly prevalent among 
certain subgroups.  Among people living with HIV, for example, the prevalence of 
cigarette smoking is estimated to be 40-70% (Collins et al., 2001; Gritz et al., 2004; 
Mamary et al., 2002; Burkhalter et al., 2005; Crothers et al., 2005; Lifson et al., 2010).  In 
addition to being pervasive, cigarette smoking is associated with a variety of morbidities, 
as well as mortality among smokers with HIV.  The introduction of new antiretroviral 
therapy regimens in recent years has resulted in a decrease in AIDS-related mortality and 
increase in life expectancies, transforming HIV from a death sentence into a chronic, 
medically manageable disease (Institute of medicine, 2001; Palella et al., 1998).  Along 
with increased life expectancies, non-AIDS-related conditions have had the time to 
emerge among this group.  Many smoking-related conditions, such as chronic obstructive 
pulmonary disease (Lewden et al., 2005; Diaz et al., 2002; Crothers et al., 2006), 
bacterial pneumonia (Crothers et al., 2005; Lifson et al., 2010; Miguez-Burbano et al., 
2005), lung cancer (Lifson et al., 2010; Kirk et al., 2007; Chaturvedi et al., 2007; Engels 
et al., 2006), and cardiovascular disease (Lifson et al., 2010; Lewden et al., 2005; 
Petoumenos et al., 2011; Barbaro et al., 2003; Friis- Møller et al., 2003; Savès et al., 
2003), among other conditions, are observed with increasing frequency among people 
living with HIV.  In fact, lung cancer is the third most commonly diagnosed cancer 
among HIV-positive persons, behind the AIDS-defining cancers Kaposi sarcoma and 
non-Hodgkin lymphoma (Kirk et al., 2007).  Moreover, cigarette smoking is associated 
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with death among people living with HIV HIV: smokers with HIV lose more life-years to 
smoking than they do to HIV (Helleberg et al., 2013).  When considering the deleterious 
nature of these health consequences, encouraging smoking cessation and understanding 
the processes that underlie cessation in this population are of importance.   
In 2010, 52.4% of adult smokers attempted to quit smoking (CDC, 2011b).  
Cessation attempt success can vary, based at least in part on the cessation method or 
methods employed.  Smoking cessation methods can include, but are not limited to, 
counseling/therapy interventions, nicotine replacement therapy (NRT; e.g., the nicotine 
patch, nicotine gum), pills or medications (e.g., varenicline/Chantix, bupropion/Zyban) 
and quitting “cold turkey”—quitting all at once without the use of therapy, NRT, or 
medications.  Research has shown that smokers who seek assistance (i.e., utilize 
counseling/therapy, NRT, or medications) have more than twice the success with 
cessation at 12 months compared to smokers who did not seek assistance (Zhu et al., 
2000).  Despite evidence indicating the efficacy of conventional smoking cessation 
modalities (i.e., behavioral and medication treatments, alone and in combination) in 
healthy smokers, research on smoking cessation among people living with HIV is scarce, 
and results have been mixed (Niaura et al., 2012).  Differences in effectiveness of 
cessation interventions between healthy smokers with HIV may arise from a variety of 
sources: additional obstacles to cessation among those with HIV including comorbid 
psychiatric conditions, comorbid substance use, lower socioeconomic status, and 
diminished access to care (Reynolds, 2009; Humfleet et al., 2009); the continued 
perception of providers that smoking cessation is not a priority among individuals living 
with HIV; reluctance to utilize medication therapies for cessation due to existing pill 
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burden; and adverse drug-drug interactions.  Understanding the determinants of stopping 
smoking, and the determinants of choosing to utilize smoking cessation aids and the 
subsequent effectiveness of these cessation aids, is critical to designing and continuing to 
improve interventions (Vangeli et al., 2011) and improving the life expectancy and 
quality of life of smokers with HIV. 
 Research examining factors associated with smoking cessation attempts has 
largely been conducted in the general population, and findings from these studies have 
been mixed.  Findings can be considered mixed in the sense that the same characteristics 
have not been consistently identified from study to study, and furthermore, even when the 
same characteristics are identified, the direction of the associations are not necessarily 
consistent (Vangeli et al., 2011).  Nevertheless, some studies have identified 
demographic characteristics such as gender (Zhou et al., 2009), age (Hatziandreu et al., 
1990; Li et al., 2010; Li et al., 2011), race/ethnicity (Fu et al., 2005; Li et al., 2010; Li et 
al., 2011), education (Hatziandreu et al., 1990; Li et al., 2011), and income (Li et al., 
2011) as being associated with making prior quit attempts.  Additionally, studies have 
shown that factors such as intention to quit (Li et al., 2010; Li et al., 2011; Zhou et al., 
2009; Hagimoto et al., 2009; West et al., 2001; Emmons et al., 2000), motivation to quit 
(Zhou et al., 2009; West et al., 2001), and confidence in success in quitting (Li et al., 
2010; Li et al., 2011; Hagimoto et al., 2009), as well as characteristics related to smoking 
itself like enjoyment of smoking too much to try to quit (Li et al., 2010; Li et al., 2011; 
Fidler et al., 2010), the number of cigarettes smoked per day (Li et al., 2010; Li et al., 
2011; Hagimoto et al., 2009; Hellman et al., 1991; Cokkinides et al., 2005), and the 
presence of nicotine dependence (Li et al., 2011; Zhou et al., 2009; Hagimoto et al., 
124 
2009; Emmons et al., 2000).  Additionally, past quit attempts are consistently identified 
as being significantly associated with making further attempts (Norman et al., 1999; 
Balmford et al., 2010; Li et al., 2010; Zhou et al., 2009; Hagimoto et al., 2009; West et 
al., 2001; Vangeli et al., 2011), with those making a quit attempt in the past year being 
more than twice as likely to make a subsequent attempt (Vangeli et al., 2011).  
 Though factors associated with making quit attempts, and specifically using NRT 
or pills/medications, have been explored in the general population, little is known about 
how factors influence quit attempt behaviors among people living with HIV.  Moreover, 
existing research is lacking in terms of investigations into social level characteristics that 
are associated with quit behaviors.  Increased knowledge of such characteristics may aid 
in the development, implementation, and continued improvement of smoking cessation 
interventions that are tailored toward people living with HIV.   
To address the gaps in the literature, the aim of the present paper was to explore 
and identify the individual- and social-level characteristics associated with prior quit 
attempts using NRT or medications for smoking cessation among a sample of current 
cigarette smokers living with HIV.  We hypothesized that individual-level characteristics, 
similar to those found among research in the general population (e.g., age, race), as well 
as social-level characteristics (e.g., significant others’ past use of NRT or medications) 
would be associated with prior quit attempts using NRT or medications for smoking 
cessation.  The aforementioned hypotheses, in addition to being shaped by prior research 
findings, were based on elements of two existing conceptual frameworks: Social 
Cognitive Theory (SCT; Bandura, 1986) and the Ecological Model for Health Promotion 
(McLeroy et al., 1988).  SCT is a learning theory that posits that individual behavior, 
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personal characteristics (i.e., individual-level characteristics), and environmental 
characteristics (i.e., social-level characteristics) can all reciprocally influence one 
another.  Similarly, the Ecological Model for Health Promotion states that behavior is 
influenced by a variety of levels of influence, including Intrapersonal and Interpersonal 
factors (i.e., individual- and social-level characteristics, respectively).  This theoretical 
background points to the possibility for significant associations between individual- as 
well as social-level characteristics and past quit attempts with NRT/medications. 
 
5.2 Methods 
5.2.1 Data Source 
Data for this dissertation aim came from the BEACON (BEing Active & 
CONnected) study, a study conducted in Baltimore, Maryland (2006-2012) aimed at 
examining social environmental influences on former and current drug users’ HIV 
medication adherence and health outcomes.  The study had three visits (baseline, 6-, and 
12-month follow-up visits) and recruited two different types of participants: Index 
participants and Supporter participants.  Index participants were recruited from clinic and 
community venues, and had to be HIV-positive, 18 years of age or older, and receiving 
HIV treatment (i.e., having taken at least one medication for HIV treatment at least one 
time within the past month) at the time of study enrollment.  In addition to self-reporting 
information, Index participants nominated their main Supporter (i.e., their main 
supportive tie who provides assistance in living with the Index’s HIV diagnosis), and 
with approval from the Index, Supporters were invited to take part in the study as well.  
Supporter participants had to be 18 years of age or older, know that the Index has HIV, 
126 
and not be a paid service provider to the Index.  Data were collected by trained 
interviewers via audio computer-assisted self-interviewing (ACASI). Index and 
Supporter dyads were administered questionnaires at the same time points.  
 The questionnaires administered at each of the time points gathered information 
on a variety of topics, including but not limited to: medication adherence, illegal drug 
use, and mental health variables.  Since the 6-month follow-up visit contained more 
extensive information regarding cigarette smoking than either the baseline visit or 12-
month follow-up visit the present study used data from the 6-month follow-up visit.  The 
Institutional Review Board at Johns Hopkins University Bloomberg School of Public 
Health approved this study.   
5.2.2 Measures 
5.2.2.1 Individual-level variables 
Sociodemographic variables - Sex was dichotomized (male/female), and age was 
categorized into approximate quartiles (28-44; 45-49; 50-53; 54-65).  Race was 
dichotomized as “Black” and “non-Black” due to sample distribution.  Past month 
income from all sources, including food stamps was dichotomized (<$500 versus >$500).  
Marital status was also dichotomized as “not married” versus “married or in a committed 
relationship”. 
Drug and alcohol use – Dichotomous variables (yes/no) were created for past 
month use of alcohol, and extramedical use of opiates, marijuana, tranquilizers or 
barbiturates, stimulants, heroin, cocaine or crack, prescription drugs, hallucinogens, and 
“other drugs”.  A dichotomous variable (yes/no) was also created for “any past month 
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drug use”, not including alcohol, as well as for past 6-month injection drug use.   
Depressive symptoms – Depressive symptoms were measured using the Center for 
Epidemiologic Studies Depression Scale (CES-D).  The CES-D is a (20 item) self-report 
scale designed to measure depressive symptomatology in the general population (Radloff, 
1977).  Possible scores range from 0 to 60, with higher scores indicating the presence of 
greater symptomatology.  A score of 16 or higher was used to identify individuals with 
clinically meaningful depressive symptoms (Radloff, 1977).  In prior studies, the CES-D 
has been shown to have good psychometric properties: for instance, it has demonstrated 
very good internal consistency reliability (>0.85) and acceptable test-retest reliability 
(Radloff, 1977; Hann et al., 1999) as well as moderate-good (0.44-0.75) concurrent 
validity compared with other scales measuring depressive symptoms (Radloff, 1977), 
good discriminant validity (Weissman, 1977), and sensitivity of 0.95 and specificity of 
0.70 when compared with the Diagnostic Interview Schedule for DSM-IV (Thomas et al., 
2001).  Moreover, the CES-D has been shown to be valid and of utility among samples 
similar to the one used in the present work (Thomas et al., 2001; Yang et al., 2013; 
Latkin et al., 2012). 
HIV primary care visits & drug treatment utilization – The number of HIV 
primary care visits made in the past 6 months was used as a categorical variable with 
three levels (0-2; 3-4; 5+).  Utilization of 12-step programs in the past 6 months was 
dichotomized (yes/no). 
Cigarette smoking - Participants were asked whether they had used NRT or 
pills/medications for the purpose of smoking cessation in the past.  A dichotomous 
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(yes/no) variable was created based on the responses.  Participants were also asked about 
the number of cigarettes that they smoke per day (i.e., cigarettes per day; CPD) (<1; 1-10; 
11-20; 21+), as well as how soon after waking they smoke their first cigarette of the day 
(i.e., time to first cigarette; TTFC) (<5 minutes; 6-30 minutes; 31-60 minutes; and 60+ 
minutes). 
The Heaviness of Smoking Index (HSI; Heatherton et al., 1989), a measure of 
nicotine dependence was created using the CPD and TTFC measures.  Scores for the HSI 
range from 0 to 6, with higher scores indicating higher levels of nicotine dependence.  
Congruent with prior research (Chaiton et al., 2007), the HSI was categorized into a 3-
category variable: low (0-1), medium (2-4), and high (5-6).  When considering the 
psychometric properties of this measure, the HSI has been shown to have good sensitivity 
(0.79) and specificity (0.96), good test-retest (0.72) reliability over a 3-year period 
(Borland, 2010), and good concordance (Cohen’s kappa=0.74) with the Fagerström Test 
for Nicotine Dependence (Heatherton et al., 1989), the most widely used measure of 
nicotine dependence (Chabrol et al., 2005). 
5.2.2.2 Dyadic-level variables 
Dichotomous variables were created based on Index participants’ responses to a 
question asking if their main partner currently smoked (yes/no), as well as based on 
Supporters’ responses to a question asking if they currently smoked (yes/no). Supporters 
who were current smokers were asked two additional questions, from which two 
dichotomous (yes/no) variables were created: (1) whether the main Supporter was 
currently interested in quitting smoking and; (2) whether the main Supporters had used 
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NRT or pills/medications for the purpose of smoking cessation in the past.  Not all 
participants reported having a main partner or a main Supporter.  Approximately half 
(54%) of smokers reported having a main partner and 63% had a main Supporter 
participant.  In order to utilize the full sample of current smokers (n=269), the two 
dyadic-level variables were coded as “0” (i.e., “no”) for individuals without partners or 
Supporters.  This was deemed reasonable, since the Index participants without main 
partners or Supporters would not have had the influence of cigarette smoking by partners 
or Supporters in their lives.  Additional sensitivity analyses were performed to assess 
whether this assumption was reasonable. 
5.2.2.3 Family-level variables 
  Index participants were questioned about the following topics: prevalence of 
smoking among family members; encouragement to smoke by family members; family 
members’ belief that smoking causes health problems; whether family members dislike 
cigarette smoking; and whether family members have rules regarding where someone can 
or cannot smoke within their homes.  Dichotomous (yes/no) variables were created based 
on responses to each of the aforementioned questions. 
5.2.3 Statistical Analysis 
 Descriptive statistics were used to describe the sample.  Chi-square (χ2) tests were 
used to assess the statistical significance of relationships between current cigarette 
smoking status and individual-level, dyadic-level, and family-level variables.  Unadjusted 
and adjusted logistic regression analyses were used to calculate odds ratios (ORs), 
adjusted odds ratios (aORs), and corresponding 95% confidence intervals (CI).  Variable 
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selection for the adjusted model was based on a combination of findings from the prior 
literature, a priori theory, and χ2 p-values of <0.05.  Variables selected for the adjusted 
model included: sex, age, race, marital status, income, nicotine dependence, and main 
Supporter’s past use of NRT and/or pills/medications for smoking cessation. 
 Of the 359 individuals followed up at the 6-month time point, 269 were current 
smokers and had provided information on prior use of NRT and pills/medications for 
smoking cessation.  These 269 individuals were retained for the present analysis.  
Additional analyses were also performed among only those current smokers who had a 
main Supporter (n=169) in an effort to assess how the decision to code the two dyadic-
level variable for Supporter smoking status as “0” (i.e., “no”) for individuals without 
Supporters may have affected results.  All analyses were performed using STATA SE 
statistical software version 12.0 (StataCorp, 2011). 
 
5.3 Results 
5.3.1 Sample characteristics 
 Detailed sample characteristics can be found in Table 5.1.  Most (59.5%) of 
participants reported having made a prior smoking cessation attempt using NRT or 
medications.  The majority of the sample (60.6%) was male, Black (90.7%), and 
approximately 48.6 years of age (SE=0.37).  Most (81.0%) reported a past month income 
greater than $500 and were unmarried (68.4%).  Significant differences between 
participants who had used NRT/medications for cessation in the past and those who had 
no prior use were observed on the basis of sociodemographic characteristics.  For 
instance, participants who had used NRT or medications in the past were more likely than 
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those who had not to report non-Black race (χ2 (1, N = 269) = 4.81, p = 0.028).  
Additionally, individuals who had made prior quit attempts with NRT or medications 
were more likely than those who had not to have a Supporter who was interested in 
quitting (χ2 (1, N = 269) = 5.99, p = 0.014).  And lastly, participants who had made prior 
quit attempts using NRT or medications were more likely than those who had not made 
attempts to have a main Supporter who had also made quit attempts using NRT or 
medications (χ2 (1, N = 269) = 5.85, p = 0.016).   
 
5.3.2 Cigarette smoking characteristics 
 Cigarette smoking characteristics are listed in Table 5.2.  A majority of smokers 
(75.8%) reported smoking a half a pack of cigarettes or less (1-10) per day, and 34% 
smoked their first cigarette of the day within 5 minutes of waking.  According to the HSI, 
more than half (64.2%) of smokers were deemed to have a medium-level of nicotine 
dependence.  When dichotomized by past use of NRT/medications for smoking cessation, 
no significant differences were found between groups on the basis of smoking 
characteristics. 
 
5.3.3 Drug use 
 Information regarding drug and alcohol use characteristics can be found in Table 
5.3.  Forty percent of participants used alcohol within the past month.  Additionally, 
approximately half of participants (51.3%) reported past month use of any drug(s), not 
including alcohol.  The most commonly used substances in this sample were 
cocaine/crack cocaine (33.1%), heroin (23.4%), and marijuana (23.4%).  In terms of 
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differences in substance use prevalence between those who had made quit attempts using 
NRT or medications and those who had not, individuals who had made prior quit 
attempts using NRT or medications were more likely than those who had not made such 
prior attempts to have used tranquilizers/barbiturates in the past month (χ2 (1, N = 269) = 
5.54, p = 0.019).  Conversely, individuals who had not made a past quit attempt were 
more likely than those who had to have used marijuana in the past month (χ2 (1, N = 269) 
= 4.80, p = 0.028). 
5.3.4 Logistic regression analyses 
 Information on associations between past smoking cessation attempts using NRT 
or medications and various covariates is presented in Table 5.4.  In adjusted analyses, 
though not observed for all age subgroups, older age (45-49: aOR=3.44, 95% CI=1.60-
7.39; 54-65: aOR=2.74, 95% CI=1.22-6.17) was positively associated with having made 
prior smoking cessation attempts using NRT or medications.  Individuals of non-Black 
race were significantly more likely to have made prior cessation attempts using NRT or 
medications than were individuals of Black race (aOR=3.61, 95% CI=1.23-10.62).  
Additionally, individuals with a main Supporter who had made prior cessation attempts 
using NRT or medications were significantly more likely to have made prior cessation 
attempts using NRT or medications themselves (aOR=2.40, 95% CI=1.24-4.63). 
5.3.5 Sensitivity analyses 
 In adjusted analyses, when restricting the sample to smokers who had a main 
Supporter (n=169), main findings did not differ markedly from findings from analyses 
utilizing the full sample (n=269).  To be more specific, in the restricted sample, older age 
(age 45-49: aOR=3.28, 95% CI=1.28-8.39; age 50-53: aOR=2.85, 95% CI=1.05-7.76) 
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and non-Black race (aOR=6.59, 95% CI=1.32-32.79) were positively associated with 
prior use of NRT or medications for smoking cessation.  Additionally, having a Supporter 
who used NRT or medications for cessation in the past significantly increased the 
likelihood that the Index had used NRT or medications for cessation in the past 
(aOR=2.24, 95% CI=1.08-4.62).  There were no discrepant findings observed between 
findings from the full and restricted samples. 
 
5.4 Discussion 
Findings from the present study identified individual- and social-level 
characteristics associated with past smoking cessation attempts using NRT or 
medications among a sample of cigarette smokers living with HIV.  In terms of 
individual-level characteristics, older age and non-Black race were associated with an 
increased likelihood of having made a prior attempt using NRT or medications.  Both 
findings are consistent with prior research.  For example, Li and colleagues (2010; 2011) 
found that older individuals were more likely to have made a prior quit attempt, while Fu 
and colleagues (2005) and Zhu and colleagues (2000) found that individuals of Black and 
Hispanic race/ethnicities were less likely than Whites to have used NRT or medications 
during a quit attempt in the past year.  Findings related to age are rather intuitive: though 
we cannot verify length of smoking history, older smokers presumably have a longer 
smoking history than do younger smokers, thereby allowing for more time during which 
smoking cessation aids could be utilized.  In addition, older adults may be more likely to 
have developed medical sequelae related to smoking that may have prompted them to 
attempt to quit.  The racial disparities observed in this analysis were not explained by 
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sociodemographic (e.g., sex, age, income, marital status) or physiologic (e.g., level of 
nicotine dependence) factors measured in this study.  In other samples, findings related to 
race/ethnicity may reflect issues related to access to healthcare settings in which use of 
NRT or medications for cessation are provided and recommended as well as other issues 
like knowledge of and comfort using medication for smoking cessation.  This, however, 
seems unlikely in a sample in which all participants are actively engaged in HIV primary 
care. However, some research has found racial disparities in use of services and physician 
treatment even among Medicare recipients (Gornick et al., 1996) and other individuals 
with apparent access to care (Bach et al., 2004).  Additionally, factors related to physician 
characteristics and training, interest and understanding of the importance of smoking and 
medical illness among people living with HIV, and whether it is considered a priority 
related to other medical problems among people with HIV may be factors to consider that 
may explain some of this differences. Additional research is needed to explore and 
explain racial/ethnic disparities in utilization of NRT or medications for smoking 
cessation.   
A novel outcome was observed in terms of social-level characteristics and their 
association with use of NRT or medications in the past.  We found that Index participants 
who had a main Supporter who had previously used NRT or medications for smoking 
cessation were more likely to have made a cessation attempt using NRT or medications 
themselves.  Such a finding points to the potential importance of social environmental 
characteristics in influencing smoking behaviors among HIV-positive cigarette smokers, 
and has implications for the development of smoking cessation interventions.  Though, 
given the cross-sectional nature of the study, we are unable to assert whether Supporter 
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cessation attempts influenced Index cessation attempts or vice versa, interventions that 
include a social component, namely ones including participation of Supporter individuals, 
may be of utility. 
Findings from the present study should be interpreted in the context of several 
limitations.  As mentioned above, this research utilizes cross-sectional data; therefore 
causal relationships between variables cannot be determined.  All data were collected via 
self-report, which allows for the possibility for social desirability and recall biases to be a 
concern.  Additionally, the survey did not contain questions to allow for the collection of 
sociometric social network data (i.e., survey data where the entire community is 
interviewed, and all members are questioned regarding their contacts within the 
community) (Wasserman & Faust, 1994).  With this sort of data, it would have been 
possible to obtain additional information about this sample, including the prevalence of 
cigarette smoking within the extended network, the types of relationships that smokers in 
the network have with the Index participants, and the specific kind of support provided 
by smokers in the network.  The survey also did not contain questions about past quit 
attempts using other assisted cessation methodologies (e.g., therapy/counseling, etc.) 
unassisted attempts (i.e., quitting “cold turkey”), or the relative success of past quit 
attempts, which would have been useful.  Finally, some of the analyses may had have 
limited statistical power. 
Despite these limitations, the present study has a number of strengths that should 
be noted as well.  Results from this study make a contribution to the extant literature 
concerning factors that are associated with cigarette smoking behaviors among a 
population exhibiting an unduly high prevalence of cigarette smoking.  Moreover, the 
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vast majority of prior work in this area has focused on characteristics associated with 
current smoking status, while the present study focused on examining another cigarette 
smoking behavior about which not much is known in this population: prior smoking 
cessation attempts using NRT or medications.  This study further extends the literature by 
investigating and identifying social environmental variables associated with smoking 
behaviors, in addition to previously researched individual-level characteristics.  
Moreover, this study focuses on and provides information on a typically hard-to-reach 
population among which cigarette smoking is a significant public health concern.   
Findings from this study confirm prior research among the general population 
showing that various individual-level characteristics, such as age and race/ethnicity, are 
associated with having made prior quit attempts using NRT or medications.  The results 
from the present study also extend existing research by demonstrating that social-level 
characteristics, like prior use of NRT or medications for cessation by main Supporters, 
are also associated with smoking behaviors among a sample of HIV-positive smokers.  In 
addition to characteristics of the individual, findings emphasize that members of an 
individual’s social network may influence their smoking behaviors.  Ultimately, 
characteristics traditionally associated with smoking cessation attempts are associated 
with attempts among HIV-positive smokers.  These results indicate that strategies 
successfully employed in other populations may be of utility among people living with 
HIV and should be reinforced to fit the needs of smokers living with HIV (Encrenaz et 
al., 2010).  Additionally, in light of the findings from the present study, smoking 
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Table 5.1. Characteristics of current smokers living with HIV, stratified by prior quit 
attemptsa (NRT or medications), BEACON, 2006-2012 (n=269) 
 Total 
Sample 








  n (%) n (%)  
Characteristic     
Individual-Level     
Sex     
Male 163 (60.6) 70 (64.2) 93 (58.1) 0.315 
Female 106 (39.4) 39 (35.8) 67 (41.9)  
Age     
28-44 66 (24.5) 34 (31.2) 32 (20.0) 0.113 
45-49 75 (27.9) 24 (22.0) 51 (31.9)  
50-53 71 (26.4) 30 (27.5) 41 (25.6)  
54-65 57 (21.2) 21 (19.3) 36 (22.5)  
Age (mean (SE)) 48.6 (0.37) 48.3 (0.61) 48.9 (0.46) 0.371 
Race     
Black 244 (90.7) 104 (95.4) 140 (87.5) 0.028 
Non-black 25 (9.3) 5 (4.6) 20 (12.5)  
Income     
<$500 51 (19.0) 24 (22.0) 27 (16.9) 0.291 
$500+ 218 (81.0) 85 (78.0) 133 (83.1)  
Marital status     
Not married 184 (68.4) 69 (63.3) 115 (71.9) 0.138 
Married/committed 
relationship 
25 (31.6) 40 (36.7) 45 (28.1)  
CESDb Score     
<16 163 (60.6) 63 (57.8) 100 (62.5) 0.438 
16+ 106 (39.4) 46 (42.2) 60 (37.5)  
HIV Primary Care 
Visitsc 
    
0-2 114 (42.4) 49 (44.9) 65 (40.6) 0.561 
3-4 66 (24.5) 28 (25.7) 38 (23.8)  
5-30 89 (33.1) 32 (29.4) 57 (35.6)  
12-Step Programc 149 (55.4) 64 (58.7) 85 (53.1) 0.365 
Alcohol d 110 (40.9) 43 (39.4) 67 (41.9) 0.691 
Any drug used,e 138 (51.3) 58 (53.2) 80 (50.0) 0.605 
Dyadic-Level     
Main partner smokes 117 (43.5) 49 (44.9) 68 (42.5) 0.690 
Main supporter smokes 133 (49.4) 47 (43.1) 86 (53.7) 0.087 
Main supporter 
interested in quitting 
100 (37.2) 31 (28.4) 69 (41.1) 0.014 
Main supporter made 
quit attempts in pasta 
65 (24.2) 18 (16.5) 47 (29.4) 0.016 
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Family-Level     
Smokers in family 230 (85.5) 93 (85.3) 137 (85.6) 0.945 
Encouragement to 
smoke by family 
24 (8.9) 10 (9.2) 14 (8.7) 0.905 
Smoking causes health 
problemsf 
261 (97.4) 106 (98.1) 155 (96.9) 0.522 
Dislike smoking 240 (89.2) 97 (89.0) 143 (89.4) 0.921 
Rules about smokingg 234 (87.0) 95 (87.2) 139 (86.9) 0.946 
a Prior quit attempts using nicotine replacement therapy or pills/medications 
b CESD = Centers for Epidemiologial Studies Depression scale 
c Within the past 6 months 
d Within the past 30 days 
e Not including alcohol 
f Belief held by family/friends 



















Table 5.2. Cigarette smoking characteristics of current smokers living with HIV, 
stratified by prior quit attempts (NRT or medications), BEACON, 2006-2012 (n=269) 





 n (%) n (%) n (%)  
CPDa     
<1 2 (0.7) 1 (0.9) 1 (0.6) 0.934 
1-10 203 (75.8) 82 (75.9) 121 (75.6)  
11-20 60 (22.4) 24 (22.2) 36 (22.5)  
21-30 1 (0.4) 0 (0.0) 1 (0.6)  
31+ 2 (0.7) 1 (0.9) 1 (0.6)  
Time to first 
cigarette 
    
<5 minutes 91 (34.0) 35 (32.4) 56 (35.0) 0.802 
6-30 minutes 81 (30.2) 31 (28.7) 50 (31.2)  
31-60 minutes 25 (9.3) 12 (11.1) 13 (8.1)  
60+ minute 71 (26.5) 30 (27.8) 41 (25.6)  
Nicotine 
dependenceb 
    
Low 93 (34.7) 41 (38.0) 52 (32.5) 0.644 
Medium 172 (64.2) 66 (61.1) 106 (66.2)  
High 3 (1.1) 1 (0.9) 2 (1.5)  
a CPD = cigarettes per day 














Table 5.3. Drug and alcohol use characteristics of current cigarette smokers living with 
HIV, BEACON, 2006-2012 (n=269) 
Past 30 Day Drug 
and Alcohol Use 
Total sample 
(n=269) 









89 (33.1) 40 (36.7) 49 (30.6) 0.299 
Heroin 63 (23.4) 32 (29.4) 31 (19.4) 0.058 
Stimulantsa 3 (1.1) 0 (0.0) 3 (1.9) 0.151 
Opiatesb 39 (14.5) 16 (14.7) 23 (14.4) 0.945 
Tranquilizers/ 
barbiturates 
16 (5.9) 2 (1.8) 14 (8.7) 0.019 
Marijuana 63 (23.4) 33 (30.3) 30 (18.7) 0.028 
Hallucinogens 1 (0.4) 0 (0.0) 1 (0.6) 0.408 
Prescription drugs 10 (3.7) 3 (2.7) 7 (4.4) 0.490 
Other 3 (1.1) 1 (0.9) 2 (1.2) 0.799 
Any drug usec 138 (51.3) 58 (53.2) 80 (50.0) 0.605 
Alcohol 110 (40.9) 43 (39.4) 67 (41.9) 0.691 
a Other than cocaine/crack cocaine 
b Other than heroin 















Table 5.4. Unadjusted and adjusted logistic regression analyses for the association 
between covariates and prior attempts smoking cessation attempts using NRT or 
medications among current cigarette smokers living with HIV, BEACON, 2006-2012 
(n=269) 
Characteristic ORa (95% CIb) aORc,d (95% CIb) 
Individual-Level   
Sex   
Male 1.0 1.0 
Female 1.33 (0.97-1.81) 1.26 (0.71-2.24) 
Age   
28-44 1.0 1.0 
45-49 2.26 (1.14-4.48) 3.44 (1.60-7.39) 
50-53 1.45 (0.74-2.85) 1.96 (0.91-4.20) 
54-65 1.82 (0.88-3.75) 2.74 (1.22-6.17) 
Race   
Black 1.0 1.0 
Non-black 2.97 (1.08-8.18) 3.61 (1.23-10.62) 
Income   
<$500 1.0 1.0 
$500+ 1.39 (0.75-2.59) 1.22 (0.92-1.60) 
Marital status   
Not married 1.0 1.0 
Married/committed relationship 1.67 (0.40-1.13) 0.61 (0.35-1.08) 
Nicotine dependencee   
Low 1.0 1.0 
Medium-High 1.27 (0.76-2.12) 1.34 (0.79-2.37) 
Dyadic-Level   
Main supporter made past quit 
attempts 
  
No 1.0 1.0 
Yes 2.10 (1.14-3.87) 2.40 (1.24-4.63) 
a OR = odds ratio 
b CI = confidence interval 
c aOR = adjusted odds ratio 
d  Multivariate model adjusted for sex, age, race, income, marital status, nicotine 
dependence, and Supporter quit attempts 







6. CHAPTER 6 - DISCUSSION 
This final chapter presents overviews of all four aims, including key findings 
from each study.  Next, the limitations and strengths of the dissertation are presented, 
along with the public health and policy significance of the key findings.  Finally, future 
directions are offered for research in the field. 
 
6.1 Study Overviews and Summary of Key Findings 
6.1.1 Aim 1: A Review Of The Literature Concerning HIV And Cigarette Smoking: 
Morbidity and Mortality, Associations With Individual- and Social-Level 
Characteristics, and Smoking Cessation Efforts 
 Chapter 2 presented a review of the literature concerning the intersecting fields of 
HIV and cigarette smoking.  In this review, a summary of morbidity, mortality, quality of 
life, and adverse treatment and medication adherence outcomes associated with cigarette 
smoking was presented.  Additionally, prior research concerning the individual- and 
social-level characteristics associated with cigarette smoking behaviors among people 
living with HIV was explored.  Next, literature pertaining to issues concerning smoking 
cessation was reviewed, including research related to interest in quitting among smokers 
living with HIV and previously-identified barriers to smoking cessation.  Currently 
accepted evidence-based smoking cessation treatments were discussed, followed by a 
summary of findings from cessation interventions conducted among smokers living with 
HIV.  Twelve cessation trials were summarized, with somewhat mixed results.  Last, 
gaps in the literature and directions for future research were identified.  
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6.1.2 Aim 2: The Association of Individual-Level and Social-Level Characteristics with 
Current Cigarette Smoking Status Among a Sample of People Living with HIV  
 Chapter 3 presented a study dedicated to exploring and identifying the individual- 
and social-level characteristics associated with current cigarette smoking status among a 
sample of persons living with HIV.  In this sample, the majority of participants were 
current cigarette smokers.  Participation in a 12-step program within the past 6 months, as 
well as past 30-day drug use, was positively associated with current cigarette smoking.  
Additionally, main Supporter smoking status was significantly associated with Index 
participant smoking status.  To be more precise, having a main Supporter who is a 
smoker increased the likelihood that the Index participant would also be a smoker.  A 
novel component of this study includes the inclusion of social environmental 
characteristics as potential correlates of current smoking status. 
 
6.1.3 Aim 3: Quitting and Cutting Down on Smoking: Interest Among Cigarette 
Smokers Living with HIV 
 In Chapter 4, findings from a study aimed at exploring the individual- and social-
level characteristics associated with interest in cutting down on or quitting smoking were 
presented.  In this sample of current smokers, the vast majority were interested in either 
cutting down on smoking or quitting smoking altogether.  Most exhibited a medium level 
of nicotine dependence, and had made a quit attempt in the past using pills/medications 
or nicotine replacement therapy.  Participants expressed interest in a wide variety of 
smoking cessation modalities; particularly high endorsement was given for modalities 
that included a social component.  Smokers who had made quit attempts in the past using 
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pharmacologic therapies were more likely than those who had not to be currently 
interested in quitting smoking.  Additionally, individuals who received encouragement to 
smoke from their family members were less likely to be interested in cutting down on 
smoking or quitting smoking than were those who did not receive encouragement to 
smoke.  Components of this study are innovative when considering that social 
environmental characteristics, in addition to individual-level characteristics, were 
included in the analysis as potential correlates of interest in cutting down on or quitting 
smoking. This study also examined a smoking behavior about which little is known in 
this population. 
 
6.1.4 Aim 4: Prior Smoking Cessation Attempts Using Nicotine Replacement Or 
Medication Therapies: Associations With Individual And Social Characteristics 
Among Smokers Living with HIV 
 Chapter 5 presented findings from a study concerned with the exploration and 
identification of characteristics, both individual- and social-level, associated with prior 
smoking cessation attempts using NRT or medications.  In this sample of current 
smokers, the majority had made prior quit attempts using pharmacologic smoking 
cessation aids.  Smokers exhibited a medium level of nicotine dependence.  Two 
individual-level characteristics, older age and non-Black race, were positively associated 
with having made prior quit attempts with NRT or medications.  Additionally, having a 
main Supporter who had previously used NRT or medications for smoking cessation 
increased the likelihood that Index participants had used such smoking aids in the past.  
Much like Aim 2, this analysis contributes to the literature by including social-level 
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characteristics in the models as potential correlates of past cessation attempts, as well as 




 Findings from the present dissertation work should be interpreted in the context of 
several limitations, which merit acknowledgement and discussion.  First, data utilized for 
these analyses were cross-sectional and observational in nature.  As a result, no 
statements can be made regarding the causal relationship between variables.  
Additionally, data were collected via self-report, creating potential concerns regarding 
recall and social desirability biases.  However, social desirability bias was not anticipated 
to be of great concern since the primary concern of this work was to examine cigarette 
smoking behaviors and: 1) all participants are adults and cigarette smoking is legal, and 
2) cigarette smoking is highly normative among people who are HIV-positive and use 
illegal drugs.  Regardless, in an attempt to diminish concerns surrounding social 
desirability bias, information was collected using audio computer-assisted self 
interviewing (ACASI), which has been shown to increase the likelihood of honest 
responding to questions regarding sensitive information (Macalino et al., 2002).  
Additionally, the survey from the parent study utilized in this work did not contain 
sociometric social network data (i.e., a survey in which the entire community are 
interviewed, and all respondents are asked about their contacts within the community) 
(Wasserman & Faust, 1994).  Had this sort of data been available, it may have been 
possible to obtain additional information, such as: the density of cigarette smoking in an 
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individual’s network, the types of relationship roles played by smokers in the network 
relative to Index participants, and the specific support provided by smokers to the Index.  
This type of information may have the potential to further elucidate the relationship 
between social environmental characteristics and cigarette smoking behaviors among 
HIV-positive persons.  Furthermore, given the unique nature of the study sample (i.e., all 
HIV-positive, engaged in HIV primary care at the time of enrollment), findings may not 
generalize beyond similar types of samples.  For instance,  
Though the survey utilized for this work (i.e., the survey from the 6-month 
follow-up visit) contained the most information regarding cigarette smoking of the 
surveys administered at the three time points, additional information not contained in the 
surveys could be of interest.  For instance, each of the main variables (i.e., current 
smoking, interest in cutting down/quitting, past cessation attempts) was measured using 
single items.  This is problematic for the current smoking variable, in particular, which 
was measured in a less than ideal way in the parent study used for the present dissertation 
work.  Typically, current smoking status is assessed using multiple questions (Trosclair & 
Dube, 2010): 1) has the participant smoked 100 or more cigarettes in their lifetime?; and 
2) has the participant smoked at least one cigarette within the past 30 days?.   The survey 
also did not collect information on the prevalence of cigarette smoking in the Index’s 
larger social network (i.e., outside of the Index’s family, main partner, or main 
Supporter).  Additionally, the prevalence of cigarette smoking among family members 
was assessed using a single (yes/no) question, rendering it difficult to distinguish which 
family members were the smokers, or to determine their relationship to as well as type 
and quality of relationship with the Index.  Additionally, the study contained a wide range 
156 
of information regarding main Supporter individuals, which was advantageous, but 
corresponding information regarding main partners was not available.   
 
6.3 Strengths 
 Notwithstanding the aforementioned limitations, the present dissertation work 
possesses strengths that should be discussed as well.  To begin, the first paper of this 
dissertation provided a comprehensive summary of the literature pertaining to the 
intersection of HIV and cigarette smoking.  Additionally, results from these studies make 
a contribution to the extant literature concerning the epidemiology of cigarette smoking 
behaviors among people living with HIV, a group that is disproportionately affected by 
smoking and smoking-related morbidity and mortality.  In addition to reporting the basic 
prevalence of various smoking behaviors, the present work explores and reports on 
characteristics associated with these behaviors, as well.  The majority of existing research 
concerning cigarette smoking among people living with HIV has focused on exploring 
characteristics associated with current cigarette smoking status.  Though knowledge on 
this topic is undoubtedly of interest and important, in addition to focusing on current 
smoking status, the present dissertation work extends the literature by focusing on 
smoking behaviors about which not much is known in this population: interest in cutting 
down on or quitting smoking and past use of NRT or medications for smoking cessation.  
Furthermore, the present work explores social-level characteristics associated with 
smoking behaviors, in addition to associations with individual-level characteristics 
explored in prior studies.  An additional strength includes this work’s focus on a typically 
hard-to-reach population among which smoking is a significant public health concern.  
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Furthermore, though numerous other studies of people with HIV do exist, this is one of 
the few that have survey items concerning social-level characteristics such as the ones 
examined within the present dissertation work, and allows for examination of 
associations between social-level characteristics and smoking behaviors among people 
living with HIV. 
 
6.4 Public Health Significance and Implications 
 Cigarette smoking is a public health issue for the general population of the United 
States, where it continues to be the leading preventable cause of death (CDC, 2011a).  
Smoking is an even greater concern among certain subgroups of the population, who 
exhibit an inflated prevalence of smoking compared to the general population.  Among 
people living with HIV, for instance, the prevalence of smoking is approximately two to 
three times higher than what is observed in the general population of the United States: 
40-70% versus 19% (Collins et al., 2001; Gritz et al., 2004; Mamary et al., 2002; 
Burkhalter et al., 2005; Crothers et al., 2005; Lifson et al., 2010; CDC, 2011b).  Findings 
from this work corroborate these high estimates: In Chapter 3, it was reported that 75% of 
the sample were current cigarette smokers.  Moreover, smoking among people with HIV 
is associated with elevated risks of a variety of health conditions (Lewden et al., 2005; 
Lifson et al., 2010; Kirk et al., 2007), and smokers living with HIV now lose more life 
years to cigarette smoking than to the HIV virus (Helleberg et al., 2013).  These prior 
research findings, coupled with corroborating findings from the present dissertation, 
make a strong case for the implementation of smoking cessation treatment integrated 
within the context of HIV primary care.  Since people living with HIV who are engaged 
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in HIV primary care are likely making doctor visits on a regular basis, having both 
services in the same location may increase the likelihood of promotion, uptake, and 
maintenance of smoking cessation therapies. 
 Additionally, findings from this dissertation work have implications for the 
development of targeted smoking cessation interventions that contain a social component, 
alone or in conjunction with standard, traditional smoking cessation therapies (e.g., 
counseling, non-nicotine replacement therapy, nicotine replacement therapy, etc.).  Each 
of the Aims containing statistical analyses described within the dissertation has 
statistically significant findings regarding the association of social-level characteristics 
with a variety of cigarette smoking behaviors.  Findings such as these are similar to those 
observed in the general population (Christakis & Fowler, 2008; Alexander et al., 2001; 
Unger & Chen, 1999; Mermelstein et al., 1986), indicating the importance of social 
factors in determining smoking behaviors.  Moreover, findings from Chapter 4 indicate 
that individuals in this sample of smokers living with HIV are interested in smoking 
cessation modalities that involve a social component.   
 Along with implications for the integration of smoking cessation treatment with 
HIV care and the development of cessation therapies with social components, findings 
from this work have policy implications as well.  For instance, the development of 
effective smoking cessation therapies utilizing a social component may be able to impact 
the recommended and approved effective treatments for smoking cessation among 
smokers with HIV as detailed in the document Treating Tobacco Use and Dependence: 
Clinical Practice Guidelines (Fiore et al., 2008).  Additionally, findings may have 
implications for improving educational curricula received by physicians regarding 
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tobacco treatment and counseling.  As summarized in Chapter 2, a significant proportion 
of HIV care providers reported a lack of confidence in their ability to provide cessation 
resources and advice (Horvath et al., 2012; Shuter et al., 2012), and that one source of 
this decreased confidence may be deficient training in tobacco treatment and counseling 
methods (Shuter et al., 2012b).  Additional mandated training in these methodologies 
have the potential to increase providers’ confidence in giving cessation advice, 
consequently increase the likelihood that cessation advice and resources will be provided 
effectively, and have the potential to make an impact on the disproportionately high 
prevalence of cigarette smoking among people living with HIV. 
 
6.5 Directions for Future Research 
 In the future, research examining the intersection of HIV and cigarette smoking 
should continue to be pursued, with an emphasis on the continued exploration of how 
social environmental characteristics influence smoking behaviors.  To give one example, 
in the future, collecting additional information on main partners of people living with 
HIV, and comparing characteristics of the main partners and main Supporters may prove 
to be of utility.  For instance, as found in Chapter 3 of this dissertation, main Supporter 
smoking status was associated with Index smoking status, while main partner smoking 
status was not.  Future research could investigate what differentiates these individuals, 
and attempt to identify characteristics that make Supporters optimally influential in the 
lives of the Index participants.  In the future, researchers should also consider an in-depth 
examination of how the prevalence of cigarette smoking among family and friends 
influences smoking behaviors.  In the present dissertation work, the prevalence of 
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smoking among family was assessed via a single question.  Future work may benefit 
from specifically distinguishing which family members are smokers, as well as exploring 
characteristics of the relationship between smokers in the family and Indexes.  For 
instance, it is possible that the quality and type of relationship between family members 
may have an impact on how influential the relationship is in terms of transmitting 
smoking behaviors and attitudes.  Additionally, factors like the age of influence and 
living situation may be influential (e.g., younger persons living at home with 
parents/grandparents/guardians may be susceptible to the influence of persons living in 
the home than would individuals who no longer live with their families or live alone).  In 
future work, main outcome variables (i.e., current smoking status, interest in cutting 
down/quitting, past quit attempts, etc.) should be measured using multiple items to fully 
capture more dimensions of what the outcomes entail.  Furthermore, future research 
should consider examining other forms of tobacco use among people living with HIV, in 
addition to cigarette smoking.  Some of the health effects associated with cigarette 
smoking, outlined in Chapter 2 of this dissertation, are attributable to nicotine (Arcavi & 
Benowitz, 2004; Huttunen et al., 2011), which is present in other tobacco products.   
 As mentioned in Chapter 1 of this dissertation work, only the Intrapersonal and 
Interpersonal levels of the Ecological Model of Health Promotion are represented within 
the present analyses.  Future work should consider examining variables that are 
representative of the remaining levels of the Ecological Model: Institutional (McLeroy et 
al., 1988), Community, and Public Policy.  Though Public Policy characteristics are 
likely to apply to all individuals in a given population (e.g., the prices and taxes applied 
to cigarette sales in a given state/country apply to everyone), there may be variation in 
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certain Community and Institutional characteristics.  These types of characteristics, such 
as the availability of tobacco outlets in a defined neighborhood or community (i.e., 
Community factors) or the rules regarding smoking in the workplace, bars, restaurants, 
and so on (i.e., Institutional factors), may prove to be influential of cigarette smoking 
behaviors, and may help to further identify points for interventions to reduce the 
prevalence of smoking among people living with HIV.  Additionally, in terms of Social 
Cognitive Theory (Bandura, 1986), one key aspect of the model not represented in the 
present dissertation work due to constraints of the data is self-efficacy.  Self-efficacy is 
the belief in one’s own ability to complete tasks and reach goals, and has an effect on 
numerous aspects of human behavior.  It is possible that self-efficacy would be influential 
of cigarette smoking behaviors among people living with HIV, particularly quitting 
behaiviors (Gwaltney et al., 2009).   
Additionally, the findings of this work have implications for the development of 
cessation interventions with a social component.  As a result, future research could 
consist of the development of such intervention programs, either as stand-alone 
treatments or in conjunction with traditional smoking cessation therapies, and the 
subsequent evaluation of their effectiveness in terms of aiding in smoking cessation.  In 
fact, in the Clinical Practice Guidelines, Fiore and colleagues (2008) identified several 
areas of research regarding HIV-positive smokers that require additional research, 
including evaluation of: the effectiveness of motivational interviewing and educational 
approaches to increase motivation to quit; effectiveness of medications and 
counseling/behavioral interventions for cessation and; effectiveness of community and 
social support networks in aiding motivation to quit and improving treatment outcomes. 
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